



THE UNIVERSITY OF
SYDNEY

Family Medicine Research Centre
Sydney School of Public Health



Bettering the Evaluation and Care of Health

Ischaemic Heart Disease (in patients aged 45+) in general practice April 2007 – March 2008 (12 months weighted data)

March 2016

Enquiries to: Helena Britt

Telephone: (02) 9845 8151

Explanatory notes for Problem Report

Background

This report represents a summary of the data collected from April 2007 until March 2008 inclusive. It provides information on problems managed that the GP recorded as diseases classified as Ischaemic Heart Disease (IHD) (K76014, K74001, K76003, K74004, K76008, K76013, K74002, K76007, K74007, K74006, K76011, K76015, K76005, K74003) in patients aged 45 years or over – see Table A for confidence intervals around the rubrics, and Table C for code descriptions.

Each year, BEACH collects data from around 1,000 GPs, who each records details about 100 consecutive consultations, thus providing an annual database of approximately 100,000 records.

Summary of BEACH data

BEACH Year	Number of GPs Raw (weighted)	Number of encounters Raw (weighted)	Number of problems managed Raw (weighted)	Number of medications (prescribed, GP supplied, over the counter) Raw (weighted)	Number of prescribed medications Raw (weighted)
April 1998-March 1999	984 (969.0)	98,400 (96,900.9)	145,183 (140,823.7)	107,451 (106,320.0)	91,427 (90,709.9)
April 1999-March 2000	1047 (1048.6)	104,700 (104,856.3)	156,576 (153,857.1)	113,555 (115,431.5)	96,925 (98,371.8)
April 2000-March 2001	999 (993.1)	99,900 (99,307.3)	147,518 (143,528.3)	108,179 (107,399.6)	91,602 (91,647.2)
April 2001-March 2002	983 (969.7)	98,300 (96,972.9)	144,372 (139,091.8)	102,352 (101,349.9)	85,304 (85,332.1)
April 2002-March 2003	1008 (1009.9)	100,800 (100,987.0)	149,976 (146,335.7)	103,289 (104,813.3)	83,755 (85,161.4)
April 2003-March 2004	1000 (1000.0)	100,000 (98,876.7)	150,126 (144,674.0)	103,774 (103,210.1)	85,023 (85,073.4)
April 2004-March 2005	953 (954.0)	95,300 (94,385.8)	141,489 (137,329.9)	95,672 (95,816.3)	77,913 (78,711.1)
April 2005-March 2006	1017 (1017.3)	101,700 (101,993.0)	152,802 (149,087.9)	105,340 (106,492.6)	85,600 (87,543.6)
April 2006-March 2007	930 (930.0)	93,000 (91,804.7)	140,886 (136,333.2)	93,140 (93,193.5)	75,495 (76,430.4)
April 2007-March 2008	953 (953.1)	95,300 (95,897.7)	147,724 (145,078.0)	96,488 (98,439.3)	76,440 (79,051.3)

April 2008-March 2009	1011 (1011.1)	101,100 (96,687.7)	159,412 (149,462.2)	108,545 (102,737.1)	88,458 (83,509.4)
April 2009-March 2010	988 (988.4)	98,800 (101,349.0)	155,889 (155,372.6)	103,232 (108,000.6)	79,229 (84,539.5)
April 2010-March 2011	958 (958.0)	95,800 (95,839.0)	150,909 (146,141.1)	100,584 (100,816.6)	80,712 (81,542.5)
April 2011-March 2012	984 (984.0)	98,400 (99,030.0)	154,963 (152,285.5)	103,320 (106,007.5)	82,574 (85,980.4)
April 2012-March 2013	978 (977.8)	97,800 (98,563.9)	155,212 (152,517.0)	99,439 (101,064.9)	79,593 (82,078.8)
April 2013-March 2014	959 (959.0)	95,900 (95,879.0)	156,546 (151,674.6)	98,959 (98,393.6)	79,882 (80,046.0)
April 2014-March 2015	995 (995.0)	99,500 (98,728.4)	158,263 (153,132.5)	101,917 (101,776.4)	83,962 (84,455.1)

The participating GPs are randomly selected by the Australian Government Department of Health (DoH) from the Medicare Claims data of active GPs (those who provided more than 375 GP services in the previous quarter). The research instrument used for each consultation is a single page recording form. An example of the recording form can be found in Appendix 1 of the BEACH annual report, *General practice activity in Australia 2014–15* <http://ses.library.usyd.edu.au/bitstream/2123/13765/4/9781743324530_ONLINE.pdf>.

The recording form contains the following variables:

- Date of encounter
- Medicare Benefits Schedule (MBS) item number(s) charged, (up to three) / form of payment / other payment source
- Whether or not the GP saw the patient at the encounter (i.e. direct or indirect encounter)
- Patient age and sex
- Patient status (new to the practice or seen before)
- Commonwealth concession card status of patient
- Patient postcode of residence
- Non English speaking background (NESB) status
- Patient's reasons for encounter (up to three per encounter)
- Diagnoses/problems managed (up to four)
- FOR EACH PROBLEM MANAGED

- Status of each problem to the patient (new/old)
- Medications prescribed (up to four per problem)
- Over the counter medications recommended
- Medications provided/supplied by the GP
- Name, strength and regimen of each medication
- Number of repeats for each medication
- Medication status - new or continued
- Other treatments (up to two per problem)
- Pathology tests ordered (up to five)
- Imaging ordered (up to two)
- Referrals and hospital admissions (up to two).

Statistical Analysis

The confidence interval (CI) is calculated as the rate estimate $\pm (1.96 \times \text{standard error})$. The CI is interpreted as “we are 95% confident that the true population value lies between the lower and upper value”. Please note that where there were less than three observations (n) in the row, no 95% CIs are provided as data were insufficient to calculate a meaningful estimate. The analysis used procedures in SAS v9.3 that calculate standard errors which adjust for the cluster survey design¹. Keep in mind when reading the report, where BEACH data are reported in a standard set of categories (e.g. types of Medicare claimable encounters), a missing category means there were no occurrences of the event (e.g. home visits missing indicates no home visits were done for this condition/group of conditions). Also, where the most common 30 or 60 cases are listed (e.g. most frequent reasons for encounter, table 3.3), only the 30 or 60 with the highest frequency of occurrence are listed in the report. There may have been other cases with a lower frequency of occurrence which are not shown.

¹ SAS Institute. SAS/STAT® User's guide, Version 9.3. Cary, NC: SAS Institute Inc, 2012.

TABLE A: Summary of encounters with at least one IHD (listed at ICPC-2 rubric/grouper level) (in patients aged 45+) – Apr07- Mar08

This table presents: the ICPC-2 rubrics that together make up “IHD (in patients aged 45+)”, and the number of encounters in which each rubric appears at least once; and the number of encounters where IHD (in patients aged 45+) was managed at least once.

The number of observations, % of encounters, 95% CIs and the national annual estimated encounters, where at least one of the selected problem/s was managed, are provided for each ICPC rubric/grouper. An introduction to ICPC-2 is available from <http://sydney.edu.au/medicine/fmrc/icpc-2/index.php>. The denominator used to calculate the column labelled '% of all encs' is also provided as a footnote. This represents the total number of patients with the selected characteristic/s of interest (e.g. age, sex, state Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem are based.

The “National annual estimated encs” gives the estimated number of encounters in a year for general practice across Australia, at which the condition is managed. It is calculated as [*the number of encounters with at least one specified condition managed (n) / the total number of recorded encounters within the specified study period*] X *the number of general practice consultations claimed from Medicare in the specified year*. If you have requested encounters for selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

The table below lists the number of non-specialist GP Medicare services for each financial year (July-June). These numbers are used for each specified BEACH year (April-March). If your report is based on multiple BEACH years (e.g. 2003–04 to 2005–06) the rate has been extrapolated to the *average* annual GP consultations over the multiple years, e.g. (96,300,000 + 98,200,000 + 101,100,000) / 3.

	BEACH year	Annual GP consultations[^]
1	1998–99	102,600,000
2	1999–00	101,500,000
3	2000–01	100,600,000
4	2001–02	99,900,000
5	2002–03	96,900,000
6	2003–04	96,300,000
7	2004–05	98,200,000
8	2005–06	101,100,000
9	2006–07	103,400,000
10	2007–08	109,500,000
11	2008–09	113,000,000
12	2009–10	116,600,000
13	2010–11	119,200,000
14	2011–12	123,900,000
15	2012–13	128,700,000
16	2013–14	134,200,000
17	2014-15	139,400,000

[^]Annual GP consultations are rounded to the nearest 100,000.

Available online at: <<http://health.gov.au/internet/main/publishing.nsf/Content/Quarterly-Medicare-Statistics>>

TABLE B: Summary of IHD (listed at ICPC-2 rubric/grouper level) (in patients aged 45+) – Apr07- Mar08

This table provides a similar output to that of table A, except it is problem-based. It counts each problem once, even when more than one problem classified as IHD (in patients aged 45+) is managed at an encounter. The number of observations, % of selected problems, per 100 of all encounters, 95% confidence intervals, the % of all problems and the national annual estimate of the listed problems managed by GPs (for each ICPC rubric and for the total selected morbidity) annually across Australia in the period used in this analysis. The denominator used to calculate the column labelled '*per 100 all encs*' is provided as a footnote. This represents the total number of patients with the selected characteristic/s of interest (e.g. age, sex,

state, Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem is based. The denominator used to calculate the column labelled '*% of all problems*' is also provided as a footnote. This represents the number of problems managed at encounters with patients who have the characteristic/s of interest (e.g. age, sex, state, Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem is based.

The "national annual estimated probs" gives the estimated number of GP contacts with the specified condition in the selected year across Australia. It is calculated as [*the number of specified problems managed (n) / the total number of recorded encounters within the specified study period*] X *the number of general practice consultations claimed from Medicare in the specified year*. If you have requested encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

TABLE C: Summary of IHD (listed at ICPC-2 rubric/grouper level) (in patients aged 45+) – Apr07- Mar08

This table has been included for your information, to show how GPs express the concept of problems classified to IHD (in patients aged 45+). Information on the BEACH coding system - ICPC-2 PLUS can be found at <http://sydney.edu.au/medicine/fmrc/icpc-2/index.php>. Statistical work should rely on tables A and B (the classified data) rather than on the terms used by GPs to describe the concept (table C). Refer to table B for the calculation used for the "national annual estimated probs".

SECTION 1: SUMMARY OF DATABASE & GENERAL PRACTITIONERS

TABLE 1a: Summary of data base: services – IHD (in patients aged 45+) – Apr07-Mar08

A frequency count, rate per 100 encounters (%), and 95% CI for each data point are reported.

Definitions of the categories are as follows:

Encounter (enc): Any professional interchange between a patient and a GP.

Direct encounters: Encounters where there is a face-to-face meeting of the patient and the GP.

No charge: Encounters where no fee (Medicare, other source, or patient) was charged for the service provided.

MBS items by GPs: This includes encounters claimable through the MBS or the Department of Veterans' Affairs (DVA). The following groups are claimable through the relevant MBS item numbers:

Short surgery consultations: (Level A) A short encounter which requires limited examination and management.

Standard surgery consultations: (Level B) An encounter of less than 20 minutes duration, which requires an examination of the patient and an implementation of a management plan in relation to at least one of the problems.

Long surgery consultations: (Level C) An encounter with duration between 20 and 40 minutes, which involves taking a detailed history and implementing a management plan for at least one of the problems.

Prolonged surgery consultations: (Level D) An encounter with a duration of more than 40 minutes, which involves taking an exhaustive history, a comprehensive examination, the arrangement of necessary investigations and implementing a management plan for at least one of the problems.

Home or institution visits (not RACF): Encounters that take place in the patient's home or an institution that is not a residential aged care facility (RACF), and an appropriate MBS item number is recorded.

Residential aged care facility: Encounters that take place in a RACF and a MBS RACF item number is recorded.

Case conferences: Encounters that are claimable using MBS item number for a case conference.

Chronic disease management: Encounters that are claimable using MBS chronic disease management item number(s).

GP mental health care: Encounters that are claimable using MBS GP mental health care plan item number(s).

Health assessments: Encounters that are claimable using MBS item number for a health assessment.

Incentive payments: Encounters where MBS incentive payment items are recorded.

Other items: Medicare item numbers that do not identify the place of encounter and are not covered by any of the above item numbers.

Workers' compensation: Encounters claimable through Workers' Compensation.

Other paid (hospital, state etc): All other direct services covered by other funding services e.g. insurance, employer, state health department, hospitals, etc.

Direct encounters with other health professional item only: Encounters where another health professional (e.g. practice nurse) item number was the only item number recorded though the patient was said to have been seen by the GP.

Indirect encounters: Encounters where there is no face-to-face meeting between the patient and the GP but a service is provided (e.g. telephone consult, prescription, referral).

TABLE 1a 2: Summary of data base: services – IHD (in patients aged 45+) – Apr07-Mar08

This table will only be valid if **all** of the data in this report are from the period April 2005 onwards. If the data are based on years prior to and including April 2005, this table is not valid. The reason is that prior to April 2005 only one item number could be recorded on an encounter form. From April 2005 onwards, up to three Medicare item numbers could be recorded. The denominator for the column titled “per 100 encs” is all encounters (from Table 1a). This table may be useful when allocating direct costs against management of a selected problem.

TABLES 1b1 & 1b2: Summary of data base: patients – IHD (in patients aged 45+) – Apr07-Mar08

Number of observations (n), percentage of total patients, and 95% CI for each data point are reported.

This table describes the characteristics of the patients whose encounters are included in this report.

Sex and age distributions are reported. The age groupings correspond with significant health issues in the life span.

HCC card: Encounters with patients who hold an Australian Government Commonwealth concession card (“Health Care Card”).

VA card: Encounters with Repatriation Health Card holders (not necessarily charged through Veterans’ Affairs (VA)).

NESB (non-English speaking background): Encounters with patients whose primary language spoken at home is not English.

Aboriginal and/or TSI: Patients who regard themselves as an Aboriginal person or a Torres Strait Islander, or both.

Non-indigenous: Patients who do not regard themselves as an Aboriginal person or a Torres Strait Islander.

New to practice: Patients who had not been seen previously in this practice.

Seen previously: Patients who had been seen previously in this practice.

State/territory: The State in which the patient lives, based on the postcode of residence reported by the patient.

ASGC (Australian Standard Geographical Classification) classifies the patient’s location to one of 5 categories

<<http://www.abs.gov.au/ausstats/abs@.nsf/mf/1216.0>>.

ASGS (Australian Statistical Geography Standard) classifies the patient’s location to one of 5 categories and is a recent adaptation of the ASGC.

<<http://www.abs.gov.au/ausstats/abs@.nsf/mf/1270.0.55.001>> ‘Non-major cities’ includes inner regional, outer regional, remote and very remote areas.

TABLE 1c: Summary of data base: Problem management – IHD (in patients aged 45+) – Apr07-Mar08

Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) for each data point are reported.

General practitioners is the number of GPs who recorded encounters that are included in this report (i.e. those who managed “IHD (in patients aged 45+)” within the specified data period).

Problem managed: A formal statement of the providers' understanding of a health problem presented by the patient, family or community. It can be described in terms of a disease, symptom/complaint, social problem or ill-defined condition managed at the encounter (up to four per encounter).

New problems: The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem but excluding the presentation of a problem first assessed by another provider.

Old problems: A previously assessed problem that requires ongoing care – includes follow-up for a problem or an initial presentation of a problem previously assessed by another provider.

Chronic problem: A medical condition characterised by a combination of the following characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of recurrence or deterioration, a poor prognosis, and consequences that impact on an individual's quality of life. Chronic problems are defined by the International Classification of Primary Care Version 2 (ICPC-2), according to O'Halloran et al (<http://fampra.oxfordjournals.org/content/21/4/381.long>), which is regularly updated.

Please note that while the numbers of ‘new problems’ and ‘old problems’ add to the total number of problems managed, ‘chronic problems’ are classified differently and individual chronic problems will have already been counted as either a ‘new’ or ‘old’ problem.

At least one:

Medication—problems for which at least one medication was recommended.

Other treatment—problems for which at least one treatment other than medication was given. (Immunisation injections are excluded.)

Referral—problems that the GP referred to at least one other health professional.

Imaging order—problems for which at least one imaging test was ordered.

Pathology order—problems for which at least one pathology test was ordered.

Medications: include any medications that are prescribed, advised for over-the-counter (OTC) purchase or provided from the GP's own supplies (GP supplied). Up to four medications can be recorded for each problem.

Other treatments (up to two per problem) include non-pharmacological treatments (Immunisation injections are excluded.) and are divided into:-

Clinical (e.g. advice, counselling)

Procedural (e.g. bandage, physical therapies, excisions). Immunisation injections are excluded.

Referrals (up to two per encounter) is any *new* referral or admission of the patient for this problem to:

Allied health services (e.g. physiotherapist, social worker, community services).

Specialist (e.g. surgeon, psychiatrist).

Emergency department of a hospital.

Hospital (either private or public).

Referral NOS are referrals that are not otherwise specified (i.e. they cannot be grouped in any of the above).

Pathology: Includes pathology tests ordered or undertaken in the management of this problem (Up to five per encounter).

Imaging: Includes imaging tests ordered or undertaken in the management of this problem (Up to two per encounter).

Other investigations include diagnostic procedures ordered or undertaken by the GP at the encounter e.g. “electrical tracings*”, which includes electrocardiogram and electroencephalogram.

TABLE 1d: General practitioners – Table of age by sex – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the distribution of male and female GPs that have been included in this analysis, by their age group. These data were collected from the GP Characteristics Questionnaire which is completed by all GPs participating in the BEACH project (see Appendix 2 in BEACH annual report, *General practice activity in Australia 2014–15* <http://ses.library.usyd.edu.au/bitstream/2123/13765/4/9781743324530_ONLINE.pdf>

TABLE 1e: Summary of database: GP characteristics - IHD (in patients aged 45+) – Apr07-Mar08

This table displays the characteristics of the GPs that have been included in this analysis. These data were also collected from the GP Characteristics Questionnaire.

Definitions of the categories are as follows:

Years in general practice: The number of years the GP has been in general practice.

Sessions: The number of sessions worked per week.

Practice size-Number of GPs at practice: The number of GPs in the participating GPs main practice (including the participating GP).

Practice size-FTE GPs at practice: The number of full time equivalent GPs in the participating GPs main practice (including the participating GP).

Practice state: The state which the GPs main practice is in.

ASGC of main practice (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories

<<http://www.abs.gov.au/ausstats/abs@.nsf/mf/1216.0>>.

ASGS of main practice (Australian Statistical Geography Standard) classifies the location of the practice to one of 5 categories

<<http://www.abs.gov.au/ausstats/abs@.nsf/mf/1270.0.55.001>>.

Country of Graduation: The GPs reported country of graduation.

>50% consults NESB: (non-English speaking background) the GPs assessment of the % of their consultations conducted in a language other than English.

Hold FRACGP is whether the participating GP is a Fellow of the Royal Australian College of General Practitioners.

Practice accredited is whether the practice is accredited.

SECTION 2: AGE BY SEX

TABLE 2.1.1: Age by sex of patient at encounter – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the distribution of male and female patients that have been included in this analysis, by their age group.

TABLE 2.1.2: Age/sex specific rates of IHD (in patients aged 45+) – Apr07-Mar08

This table displays the management rate of the specified condition(s) by each age–sex category. The denominator for the age sex– specific rate is the total number of encounters with patients (or specified type of patients) in each age–sex category.

TABLE 2.1.3: Patient characteristic specific rates of IHD (in patients aged 45+) – Apr07-Mar08

This table displays the management rate of the specified condition(s) by patient characteristic category, e.g. patients who are: new to practice; HCC card holders; VA card holders; of non-English speaking background; Aboriginal and/or Torres Strait Islander; and located in areas as classified by ASGC and ASGS.

TABLE 2.2: Age by sex of patient at encounter – new IHD (in patients aged 45+) – Apr07-Mar08

This table displays the age-sex distribution (similar to table 2.1) of patients who are having IHD (in patients aged 45+) managed for the first time (i.e. it is a new problem).

SECTION 3: REASONS FOR ENCOUNTER – ALL

TABLE 3.1: Number of reasons for encounter by sex of patient – IHD (in patients aged 45+) – Apr07-Mar08

Reasons for encounter (RFE) reflect the patients' expressed demand for care as perceived and recorded by the GP. Up to three RFEs can be recorded at each encounter. An RFE is not directly linked to a problem managed. This table gives the number of RFEs recorded for encounters where IHD (in patients aged 45+) was one of the problems managed. RFEs have been grouped using ICPC-2 PLUS chapter headings which correspond approximately to the main body systems with additional chapters for social and psychological problems. Problems which cross multiple body systems are grouped together as "General & unspecified".

TABLE 3.2: Reasons for encounter (RFEs) – ICPC chapter – IHD (in patients aged 45+) – Apr07-Mar08

Each RFE is coded using ICPC-2 PLUS and classified to ICPC-2. There are seventeen chapters in ICPC-2 which are mainly based on body systems. Details on these chapters can be found at <<http://sydney.edu.au/medicine/fmrc/icpc-2/index.php>>. This table shows the distribution of RFEs by ICPC-2 chapter at the encounters where IHD (in patients aged 45+) was managed.

TABLE 3.3: Top 30 reasons for encounters (RFEs) – IHD (in patients aged 45+) – Apr07-Mar08

This table shows the 30 most common RFEs recorded at the encounters where IHD (in patients aged 45+) was a problem managed. The RFE label is the individual ICPC rubric label unless denoted by *, which indicates a grouping of multiple ICPC rubrics under the same RFE (concept) label (see Appendix 4 of the BEACH annual report, *General practice activity in Australia 2014–15*, <<http://hdl.handle.net/2123/13765>>). Number of observations (n), % of total RFEs, rate per 100 encounters and 95% confidence intervals (CI) are provided for each data point.

SECTION 4: REASONS FOR ENCOUNTER – NEW

TABLE 4.1: Number of reasons for encounter by sex of patient – New IHD (in patients aged 45+) – Apr07-Mar08

This table gives the number of RFEs recorded for encounters where IHD (in patients aged 45+) was one of the problems managed and was classified as a ‘new’ problem, that is, it had not previously been dealt with by a medical practitioner.

TABLE 4.2: Reasons for encounter (RFEs) – ICPC chapter – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the RFEs by ICPC chapter (similar to table 3.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 4.3: Top 30 reasons for encounters (RFEs) – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the most common RFEs (similar to table 3.3) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

SECTION 5: PROBLEMS MANAGED - ALL

TABLE 5.1: Number of problems by sex of patient – IHD (in patients aged 45+) – Apr07-Mar08

Up to four problems managed can be recorded at each encounter. This table gives the number of problems managed by GPs at encounters with males and females where at least one of the problems managed was IHD (in patients aged 45+).

TABLE 5.2: Other problems managed – ICPC chapter – IHD (in patients aged 45+) – Apr07-Mar08

This table includes all diagnoses, diseases, ill-defined conditions and complaints, other than IHD (in patients aged 45+), managed by the GP (i.e. co-morbidity managed) at the selected encounters. The problems are listed here by ICPC chapter. Number of observations (n), % of total problems managed, rate per 100 encounters and 95% confidence interval (CI) are provided for each data point.

TABLE 5.3: Top 30 other problems managed – IHD (in patients aged 45+) – Apr07-Mar08

This table lists the 30 most common diagnoses, diseases, ill-defined conditions and complaints, other than IHD (in patients aged 45+) (i.e. co-morbidity managed), managed by the GP at the selected encounters. The problems are listed here by the individual ICPC rubric label unless denoted by *, which indicates a grouping of multiple ICPC rubrics under the same problem (concept) label, e.g. “Hypertension*” groups two ICPC rubrics of Hypertension Uncomplicated (K86) and Hypertension Complicated (K87), together with two plus codes W81002 (Hypertension; pre-eclamptic) and W81003 (Hypertension in pregnancy). (see Appendix 4 of the BEACH annual report, *General practice activity in Australia 2014–15*, <<http://hdl.handle.net/2123/13765>>). Number of observations (n), % of total problems managed, rate per 100 encounters with the selected problem and 95% confidence interval (CI) are provided for each data point.

SECTION 6: PROBLEMS MANAGED – NEW

TABLE 6.1: Number of problems by sex of patient – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the number of problems managed by patient sex (similar to table 5.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 6.2: Other problems managed – ICPC chapter – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the co-morbidities managed by the GP (similar to table 5.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 6.3: Top 30 other problems managed – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the 30 most common co-morbidities managed by the GP (similar to table 5.3) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

SECTION 7: MEDICATIONS – ALL

TABLE 7.1: Frequency of medication provision – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the distribution of medications, by the form of provision (prescribed, advised for OTC purchase, or GP supplied). Up to four medications can be recorded for each problem. Number of observations (n), rate per 100 problems managed, 95% confidence interval (CI), % of all medications and 95% confidence interval (CI) are provided for each data point.

TABLE 7.2: Top 30 medications prescribed – ATC (WHO) Level 2 (3 digits) – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the prescribed medications for IHD (in patients aged 45+) grouped according to the WHO Anatomical Therapeutic Chemical (ATC) classification index² at Level 2 (3 digits). Note: over-the-counter and GP supplied medications have not been included. Number of observations (n), rate per 100 IHD (in patients aged 45+) problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

TABLE 7.2.1: Top 30 medications prescribed – ATC (WHO) Level 3 (4 digits) – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the prescribed medications for IHD (in patients aged 45+) grouped according to the WHO Anatomical Therapeutic Chemical (ATC) classification index² at Level 3 (4 digits). Note: over-the-counter and GP supplied medications have not been included. Number of observations (n), rate per 100 IHD (in patients aged 45+) problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

TABLE 7.2.2: Top 30 medications prescribed – ATC (WHO) Level 4 (5 digits) – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the most frequently prescribed medications for IHD (in patients aged 45+) grouped according to the WHO Anatomical Therapeutic Chemical (ATC) classification index² at Level 4 (5 digits). Note: Over-the-counter and GP supplied medications have not been included. Number of observations (n), rate per 100 IHD (in patients aged 45+) problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

² Anatomical Therapeutic Chemical (ATC) classification index, WHO Collaborating Centre for Drug Statistics Methodology.

TABLE 7.2.3: Top 60 generic medications prescribed – CAPS generic (4 digits) – IHD (in patients aged 45+) – Apr07-Mar08

This table displays the most frequently prescribed medications for IHD (in patients aged 45+) grouped according to the CAPS classification index (Coding Atlas for Pharmaceutical Substances) at the generic (7 digit level). Information on the CAPS coding system can be found at <<http://sydney.edu.au/medicine/fmrc/caps/index.php>>. Note: Over-the-counter and GP supplied medications have not been included. Number of observations (n), rate per 100 IHD (in patients aged 45+) problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

TABLE 7.2.4: Prescribed medications (generic and products within each generic) – IHD (in patients aged 45+) – Apr07-Mar08

This table lists only prescribed medications using the CAPS classification index. The data are presented in three levels –

Total prescribed IHD (in patients aged 45+) medications

Generic medications recorded in the management of IHD (in patients aged 45+)

Individual product recorded in the management of IHD (in patients aged 45+)

At each level, the number of observations (n) and a percentage of total prescribed medications. For the generic and individual level, the medications are expressed as a rate per 100 problems, and a percentage of medications given for IHD (in patients aged 45+). Also, at the individual product level, the percentage of medications accounted for by each product within the relevant generic group, is shown.

TABLE 7.2.5.1: Top 60 brands of prescribed medications in alphabetic order – IHD (in patients aged 45+) – Apr07-Mar08

This table lists the medications that were prescribed for IHD (in patients aged 45+) at brand level (i.e. Over-the-counter and GP supplied medications have not been included). The medications are listed here in alphabetic order. Number of observations (n), % of prescribed medications for IHD (in patients aged 45+), rate per 100 problems managed, 95% confidence interval (CI), % of all prescribed medications and 95% confidence interval (CI) are provided for each data point. Please note that some of the medications are listed as their generic names as that is how the GP has labelled it.

TABLE 7.2.5.2: Top 60 brands of prescribed medications in frequency descending order – IHD (in patients aged 45+) – Apr07-Mar08

This table lists the medications that were prescribed for IHD (in patients aged 45+) at brand level (note: OTC and GP supplied medications have not been included). The medications are listed here in descending order of frequency. Please note that some of the medications are listed as their generic names as that is how the GP has labelled it.

TABLE 7.3: Medications (generic and products within each generic) – IHD (in patients aged 45+) – Apr07-Mar08

This table lists all medications (prescribed, OTC and GP supplied) using the CAPS classification index. The data are presented in three levels –

Total IHD (in patients aged 45+) medications

Generic medications recorded in the management of IHD (in patients aged 45+)

Individual product recorded in the management of IHD (in patients aged 45+)

At each level, the number of observations (n) and a percentage of all medications given. For the generic and individual level the medications are expressed as a rate per 100 IHD (in patients aged 45+) problems and as a percentage of medications given for IHD (in patients aged 45+) are shown. Also, at the individual product level, the percentage of medications accounted for by each product within the relevant generic group, is shown.

TABLE 7.4: Prescribed daily dose (generic level) – IHD (in patients aged 45+) – Apr07-Mar08

Medications that are prescribed by the GP, for which complete regimen and dosage (in micrograms, milligrams or grams) information are recorded, are included in the calculation of the prescribed daily dose (PDD). The number of medications (n), and the mean, median, minimum and maximum prescribed daily doses for each generic medication are shown. Please note: there will be fewer medications included in this table than in table 7.1 because complete dosage and regimen information are required for calculation of PDD.

SECTION 8: MEDICATIONS – NEW IHD (in patients aged 45+)

TABLE 8.1: Frequency of medication provision – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the distribution of medications, by the form of provision (similar to table 7.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2: Top 30 medications prescribed – ATC (WHO) Level 2 (3 digits) – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays the prescribed medications for IHD (in patients aged 45+) (similar to 7.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.1: Top 30 medications prescribed – ATC (WHO) Level 3 (4 digits) – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays the prescribed medications for IHD (in patients aged 45+) (similar to 7.2.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.2: Top 30 medications prescribed – ATC (WHO) Level 4 (5 digits) – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays the most frequently prescribed medications for IHD (in patients aged 45+) (similar to table 7.2.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.3: Top 60 generic medications prescribed – CAPS generic (4 digits) – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays the most frequently prescribed medications for IHD (in patients aged 45+) (similar to table 7.2.3) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.4: Prescribed medications (generic and products within each generic) – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists only prescribed medications (similar to table 7.2.4) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.5.1: Top 60 brands of prescribed medications in alphabetic order – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists the medications that were prescribed for IHD (in patients aged 45+) in alphabetic order (similar to table 7.2.3.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.2.5.2: Top 60 brands of prescribed medications in frequency descending order – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists the medications that were prescribed for IHD (in patients aged 45+) in frequency descending order (similar to table 7.2.3.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.3: Medications (generic and products within each generic) – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists all medications (similar to table 7.3) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 8.4: Prescribed daily dose (generic level) – New IHD (in patients aged 45+) – Apr07-Mar08

This table shows the prescribed daily doses for each generic medication (similar to table 7.4) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

SECTION 9: CLINICAL TREATMENTS & PROCEDURES

If your report is based on data from April 2005 onwards, clinical and procedural treatments are a combination of those done by the GP and the practice nurse. NB: Immunisation injections are excluded from procedural treatments.

TABLE 9.1.1: Top 10 Clinical treatments – IHD (in patients aged 45+) – Apr07-Mar08

Up to two non-pharmacological treatments can be recorded for each problem. These treatments are coded using ICPC-2 PLUS. This table lists the 10 most common clinical treatments performed by a GP for all cases of IHD (in patients aged 45+). Clinical treatments include general and specific advice, counselling or education, family planning, and administrative processes. An asterisk (*) denotes multiple ICPC-2 or ICPC-2 PLUS codes. (see Appendix 4 of the BEACH annual report, *General practice activity in Australia 2014–15*, <<http://hdl.handle.net/2123/13765>>).

TABLE 9.1.2: Top 10 Procedural treatments – IHD (in patients aged 45+) – Apr07-Mar08

This table lists the 10 most common procedural treatments recorded by a GP for all cases of IHD (in patients aged 45+). Procedural treatments include therapeutic actions and diagnostic procedures undertaken at the encounter. An asterisk (*) denotes multiple ICPC-2 or ICPC-2 PLUS codes. (see Appendix 4 of the BEACH annual report, *General practice activity in Australia 2014–15*, <<http://hdl.handle.net/2123/13765>>).

. NB: Immunisation injections are excluded

TABLE 9.2.1: Top 10 Clinical treatments – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists the 10 most common clinical treatments performed by a GP (similar to table 9.1.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 9.2.2: Top 10 Procedural treatments – New IHD (in patients aged 45+) – Apr07-Mar08

This table lists the 10 most common procedural treatments recorded by a GP (similar to table 9.1.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c). NB: Immunisation injections are excluded

SECTION 10: REFERRALS

TABLE 10.1.1: Top 10 Referrals to medical specialists – IHD (in patients aged 45+) – Apr07-Mar08

Up to two referrals or admissions can be recorded for each encounter and can be linked to one or more of the problems managed at the encounter. Only *new* referrals are recorded. Continuation referrals are not included. This table displays referrals to medical specialists for IHD (in patients aged 45+). For information on referrals to hospital, emergency department, and other medical services and referrals, please refer to table 1c.

TABLE 10.1.2: Top 10 Referrals to allied health professionals – IHD (in patients aged 45+) – Apr07-Mar08

Up to two referrals or admissions can be recorded for each encounter and can be linked to one or more of the problems managed at the encounter. Only *new* referrals are recorded. Continuation referrals are not included. This table displays referrals to allied health professionals for IHD (in patients aged 45+). For information on referrals to hospital, emergency department, and other medical services and referrals, please refer to table 1c.

TABLE 10.2.1: Top 10 Referrals to medical specialists – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays referrals to medical specialists for IHD (in patients aged 45+) (similar to table 10.1.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 10.2.2: Top 10 Referrals to allied health professionals – New IHD (in patients aged 45+) – Apr07-Mar08

This table displays referrals to allied health professionals for IHD (in patients aged 45+) (similar to table 10.1.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

SECTION 11: PATHOLOGY TESTS ORDERED

TABLE 11.1.1: Pathology orders across MBS pathology groups – IHD (in patients aged 45+) – Apr07-Mar08

This table presents all pathology tests ordered or undertaken in the management of IHD (in patients aged 45+). Tests are displayed by Medicare Benefits Schedule (MBS) group. Up to five pathology tests may be recorded at each encounter and can be linked to one or more of the problems managed at the encounter. A pathology test order may be for a single test (e.g. Pap smear, HbA1c) or for a battery of tests (e.g. lipids, full blood count). Where a battery of tests was ordered, the battery name was recorded rather than each individual test.

TABLE 11.1.2: Pathology orders at individual test level – IHD (in patients aged 45+) – Apr07-Mar08

This table presents all individual pathology tests ordered or undertaken in the management of this problem. Tests are displayed at the individual test level. Up to five pathology tests may be recorded at each encounter and can be linked to one or more of the problems managed at the encounter. A pathology test order may be for a single test (e.g. Pap smear, HbA1c) or for a battery of tests (e.g. lipids, full blood count). Where a battery of tests was ordered, the battery name was recorded rather than each individual test.

TABLE 11.2.1: Pathology orders across MBS pathology groups – New IHD (in patients aged 45+) – Apr07-Mar08

This table presents all pathology tests ordered or undertaken in the management of IHD (in patients aged 45+) (similar to table 11.1.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 11.2.2: Pathology orders at individual test level – New IHD (in patients aged 45+) – Apr07-Mar08

This table presents all individual pathology tests ordered or undertaken in the management of this problem (similar to table 11.2.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

SECTION 12: IMAGING TESTS ORDERED

TABLE 12.1.1: Imaging tests ordered by MBS group – IHD (in patients aged 45+) – Apr07-Mar08

This table presents all imaging tests ordered or undertaken for the management of IHD (in patients aged 45+). Tests are displayed by Medicare Benefits Schedule (MBS) group. Up to three imaging tests may be recorded at each encounter and can be linked to one or more of the problems managed at the encounter. A single imaging test may be ordered for more than one problem, and conversely more than one test may be ordered for the same problem.

TABLE 12.1.2: Imaging tests ordered at ICPC-2 PLUS level – IHD (in patients aged 45+) – Apr07-Mar08

This table presents all imaging tests ordered or undertaken in the management of this problem. Tests are displayed at ICPC-2 PLUS level. Up to three imaging tests may be recorded at each encounter and can be linked to one or more of the problems managed at the encounter.

TABLE 12.2.1: Imaging tests ordered by MBS group – New IHD (in patients aged 45+) – Apr07-Mar08

This table presents all imaging tests ordered or undertaken for the management of IHD (in patients aged 45+) at an MBS group level (similar to table 12.1.1) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

TABLE 12.2.2: Imaging tests ordered at ICPC-2 PLUS level – New IHD (in patients aged 45+) – Apr07-Mar08

This table presents all imaging tests ordered or undertaken for the management of IHD (in patients aged 45+) at an ICPC-2 PLUS level (similar to table 12.1.2) for encounters where IHD (in patients aged 45+) was managed and was classified as a “new problem” (see definition table 1c).

Table A: Summary of encounters with at least one IHD 45+ (listed at ICPC-2 rubric level) - Apr07-Mar08 wgt'd with national annual estimated encounters

Encounters with at least one:			ICPC-2 rubric	n	% of all encs	Lower 95% CI	Upper 95% CI	National annual estimated encs	Lower 95% CI	Upper 95% CI
IHD 45+				1018	1.93	1.71	2.16	1162000	1029000	1296000
	IHD without angina	K76	874	1.66	1.45	1.88	998000	869000	1128000	
	IHD with angina	K74	144	0.27	0.22	0.32	164000	133000	195000	

Table B: Summary of IHD 45+ (grouped by ICPC-2 rubric/grouper) - Apr07-Mar08 wgt'd with national annual estimated problems

		ICPC-2 rubric	n	% of selected problems	Per 100 all encs	Lower 95% CI	Upper 95% CI	% of all problems	National annual estimated probs	Lower 95% CI	Upper 95% CI
IHD 45+											
IHD without angina	K76	874	85.90	1.66	1.45	1.88	0.99	998000	869000	1128000	
IHD with angina	K74	144	14.10	0.27	0.22	0.32	0.16	164000	133000	195000	
Total IHD 45+			1018	100.00	1.93	1.71	2.16	1.15	1162000	1029000	1296000

Refer to explanatory notes for the base used in calculation of national annual estimated encounters, and the number of estimated encounters is rounded at the nearest 1000.

The denominators used to calculate column labelled 'per 100 all encs' and '% of all problems' are 52628 and 88325 respectively.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes
See explanatory notes (Section 3) for URL where groupings are described

Table C: Summary of IHD 45+ (listed at ICPC-2 plus code level)- Apr07-Mar08 wgted

IHD 45+	ICPC-2 plus code	n	% of selected problems	Per 100 all encs	% of all problems	National annual estimated probs
Disease;ischaemic heart	K76014	762	74.81	1.45	0.86	870000
Angina pectoris	K74001	128	12.58	0.24	0.14	146000
Coronary artery disease	K76003	88	8.61	0.17	0.10	100000
Coronary heart disease	K76013	16	1.58	0.03	0.02	18000
Angina;unstable	K74004	9	0.87	0.02	0.01	10000
Infarction;myocardial;old	K76007	6	0.61	0.01	0.01	7000
IHD with angina	K74007	6	0.61	0.01	0.01	7000
Ischaemia;myocardial;chronic	K76008	3	0.29	0.01	0.00	3000
Spasm;artery;coronary	K74003	0	0.04	0.00	0.00	1000
	
Total IHD 45+		1018	100.00	1.93	1.15	1162000

Refer to explanatory notes for the base used in calculation of national annual estimated encounters, and the number of estimated encounters is rounded at the nearest 1000.

Table 1a: Summary of data base: services - IHD 45+ Apr07-Mar08 wgt'd

Data	n	Rate per 100 encs	Lower 95% CI	Upper 95% CI
General practitioners	460	.	.	.
Encounters	1018	.	.	.
Direct encounters	926	98.0	97.0	99.1
No charge	5	0.5	0.0	1.1
MBS items by GPs	914	96.8	95.5	98.0
- Short surgery consultations	1	0.1	0.0	0.3
- Standard surgery consultations	650	68.8	64.6	72.9
- Long surgery consultations	155	16.4	13.5	19.2
- Prolonged surgery consultations	15	1.6	0.7	2.5
- Home or institution visits (not RACF)	34	3.6	1.9	5.3
- Residential aged care facility (RACF)	24	2.5	1.3	3.7
- Chronic disease management items	23	2.5	1.3	3.6
- Health assessments	10	1.1	0.2	2.0
- Incentive payments	1	0.1	0.0	0.4
- Other items	1	0.1	0.0	0.2
Worker's compensation	4	0.5	0.0	1.0
Other paid (hospital, state etc)	2	0.2	0.0	0.6
Indirect encounters	19	2.0	0.9	3.0
Missing	73	.	.	.

The indirect consultations with item numbers (e.g.: chronic disease management item or case conference item) are counted under both MBS items by GPs and indirect consultations. Therefore, the number of no charge, medicare paid, worker's compensation and other paid do not always add up to the number of direct consultations.

During the BEACH study period April 1998 to March 2005, GPs were instructed to record the lowest Medicare item number (e.g.: an A1 item number) if multiple item numbers applied.

From April 2005 onwards, multiple Medicare item numbers (up to 3) could be recorded on an encounter form. The lowest item from the encounter was selected and analysed in this table.

This provides comparable results to those reported before April 2005.

Other health professional items incl. practice nurse/aboriginal health worker/allied health services.

Table 1a 2: Distribution of grouped Medicare service item numbers - IHD 45+ Apr07-Mar08 wgt'd

From April 2005 onwards, Multiple Medicare service item numbers (up to 3) could be recorded for each encounter

Service Item Group	N (recorded items)	percent	Per 100 encs	Lower 95% CI	Upper 95% CI
Surgery consultations	821	82.5	80.7	77.6	83.7
Hospital residential aged care and home visits	58	5.8	5.7	3.7	7.7
Health assessments	14	1.4	1.4	0.5	2.3
Chronic disease management items including case conferences	37	3.7	3.6	2.1	5.1
Practice incentive payments	1	0.1	0.1	.	.
Acupuncture	1	0.1	0.1	.	.
Practice nurse/aboriginal health worker/allied health services	20	2.0	1.9	0.9	3.0
Diagnostic procedures and investigations	31	3.1	3.1	1.8	4.4
Surgical operations	3	0.3	0.3	0.0	0.8
Other items	9	0.9	0.9	0.0	2.0

Total Medicare service items recorded	995	100.0	97.8	94.5	101.0

The denominator for the column titled 'Per 100 encs' is all encounters (from Table 1a)

Table 1b: Summary of data base: patients - IHD 45+

Data	n	%	Lower 95% CI	Upper 95% CI
Patients	1018	.	.	.
- Males	631	62.5	58.9	66.0
- Females	379	37.5	34.0	41.1
- Missing sex	8	.	.	.
- 45-64 years	261	25.6	22.1	29.1
- 65-74 years	294	28.9	25.6	32.1
- 75+ years	464	45.5	41.6	49.5
- HCC card	719	73.9	69.8	78.0
- No HCC card	254	26.1	22.0	30.2
- Missing HCC	45	.	.	.
- VA card	91	9.4	7.2	11.7
- No VA card	876	90.6	88.3	92.8
- Missing VA	50	.	.	.
- NESB	127	13.2	9.3	17.1
- English speaking background	839	86.8	82.9	90.7
- Missing NESB status	52	.	.	.
- Aboriginal and/or TSI	7	0.7	0.2	1.2
- Non-indigenous	960	99.3	98.8	99.8
- Missing ATSI status	51	.	.	.
- New to practice	21	2.1	1.2	3.0
- Seen previously	985	97.9	97.0	98.8
- Missing status	12	.	.	.

Table 1b: Summary of data base: patients - IHD 45+ - Apr07-Mar08 wgted

Data	n	%	Lower 95% CI	Upper 95% CI
- ACT	2	0.2	0.0	0.6
- NSW	384	38.4	31.5	45.3
- VIC	279	27.9	20.5	35.3
- QLD	157	15.7	11.4	20.0
- SA	90	9.0	6.0	12.0
- WA	67	6.7	3.5	9.9
- TAS	11	1.1	0.3	1.9
- NT	9	0.9	0.1	1.7
- Missing state	18	.	.	.

ASGC- Major Cities	717	71.7	66.1	77.4
- Inner Regional	191	19.1	14.5	23.8
- Outer Regional	80	8.0	5.0	10.9
- Remote	10	1.0	0.2	1.7
- Very Remote	2	0.2	0.0	0.5
- Missing ASGC	19	.	.	.

ASGS- Major Cities	724	72.5	66.9	78.0
- Inner Regional	186	18.6	14.0	23.2
- Outer Regional	77	7.7	4.8	10.7
- Remote	8	0.8	0.0	1.6
- Very Remote	4	0.4	0.0	0.8
- Missing ASGS	19	.	.	.

Table 1c: Summary of data base: Problem management IHD 45+ Apr07-Mar08 wgttd

Data	n	Rate per 100 probs	Lower 95% CI	Upper 95% CI
General practitioners	460	.	.	.
Encounters	1018	.	.	.
Problem managed	1018	100.0	100.0	100.0
- New problem	86	8.4	6.4	10.5
- Old problem	932	91.6	89.5	93.6
- Chronic problem	1018	100.0	100.0	100.0
At least 1 Medication	678	66.6	62.7	70.5
At least 1 Other treatment ^	170	16.7	14.0	19.5
At least 1 Referral	124	12.2	9.8	14.5
At least 1 Imaging	21	2.1	1.0	3.2
At least 1 Pathology	158	15.5	12.7	18.3
Medications	1216	119.5	109.9	129.1
- Prescribed	1174	115.3	105.8	124.9
- Advised OTC	23	2.2	1.1	3.4
- GP supplied	19	1.9	0.5	3.3
Other treatments ^	186	18.3	15.1	21.6
- Clinical	128	12.6	9.7	15.5
- Procedural ^	58	5.7	3.6	7.9
Referrals	126	12.3	10.0	14.7
- Hospital	5	0.5	0.1	1.0
- Specialist	108	10.6	8.4	12.8
- Allied health services	5	0.5	0.0	1.1
- Emergency department	3	0.3	0.0	0.6
- Other referral	4	0.4	0.0	0.8
Pathology	387	38.0	30.3	45.7
Imaging	24	2.4	1.2	3.6

^ Excludes all local injection/infiltrations performed for immunisations/vaccinations.

Table 1d: General practitioners - IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of gpage by gpsex

gpage(GP age)	gpsex(GP sex)		
Frequency	Male	Female	Total
Row Pct			
Col Pct			
< 35 years	11.8622	13.9671	25.8293
	45.93	54.07	
	3.75	10.05	
35-44 years	49.0779	34.9852	84.0631
	58.38	41.62	
	15.53	25.17	
45-54 years	105.133	58.9624	164.095
	64.07	35.93	
	33.27	42.42	
55+ years	149.948	31.0914	181.039
	82.83	17.17	
	47.45	22.37	
Total	316.02	139.006	455.026

Frequency Missing = 5.0760626827

Table 1e: Summary of data base: GP characteristics - IHD 45+ Apr07-Mar08 wgt'd

Data	n	%
Years in general practice	.	.
<2 years	3	0.6
2-5 years	26	5.6
6-10 years	49	10.7
11-19 years	84	18.4
20+ years	295	64.6
Missing	3	.
Sessions ^	.	.
< 5 per week	56	12.2
6-10 per week	356	77.9
11+ per week	45	9.9
Missing	4	.
Practice size-Num GPs at practice*	.	.
Missing	460	.
Practice size-FTE GPs at practice**	.	.
<1	1	0.2
1-<2 FTE GPs	89	19.8
2-<3 FTE GPs	70	15.5
3-<4 FTE GPs	61	13.6
4-<5 FTE GPs	51	11.5
5-<10 FTE GPs	141	31.4
10-<15 FTE GPs	28	6.2
15+ FTE GPs	8	1.7
Missing	11	.
Practice state	.	.
ACT	2	0.4
NSW	153	33.2
VIC	120	26.2
QLD	80	17.3
SA	56	12.1
WA	30	6.5
TAS	12	2.5
NT	8	1.7

^ Number of sessions worked per week not collected after Mar09

* Practice size-Num GPs at practice not collected between Apr07-Mar09

** Practice size-FTE GPs at practice not collected prior to Apr07

Table 1e: Summary of data base: GP characteristics - IHD 45+ Apr07-Mar08 wgted

Data	n	%
ASGC of main practice	.	.
Major Cities	316	68.6
Inner Regional	96	20.8
Outer Regional	37	8.1
Remote	8	1.8
Very Remote	3	0.7
ASGS of main practice	.	.
Major Cities	319	69.3
Inner Regional	92	20.1
Outer Regional	41	8.8
Remote	3	0.6
Very Remote	5	1.1
Country of graduation	.	.
Australia	344	75.0
New Zealand	9	2.0
Asia	38	8.3
UK/Ireland	32	7.0
America	1	0.2
Europe	14	3.1
Africa	17	3.7
Pacific	2	0.4
Other	1	0.2
Missing	2	.
> 50% consultations NESB	.	.
Yes	12	2.7
No	445	97.3
Missing	3	.
Hold FRACGP	.	.
Yes	198	43.3
No	259	56.7
Missing	3	.
Practice accredited	.	.
Yes	404	88.2
No	54	11.8
Missing	2	.

^ Number of sessions worked per week not collected after Mar09

* Practice size-Num GPs at practice not collected between Apr07-Mar09

** Practice size-FTE GPs at practice not collected prior to Apr07

Table 2.1.1 Age by gender of patient at encounter - IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of sex by agegp

sex(Sex of patient)
agegp(Patient Age-group)

Frequency				
Row Pct				
Col Pct	45-64	65-74	75+	Total
Male	185.483	187.068	258.398	630.949
	29.40	29.65	40.95	
	71.67	64.26	56.14	
Female	73.3187	104.049	201.901	379.268
	19.33	27.43	53.23	
	28.33	35.74	43.86	
Total	258.802	291.117	460.299	1010.22

Frequency Missing = 7.7225786677

Table 2.1.2 Age/sex specific rates of IHD 45+ Apr07-Mar08 wgted

Patient characteristics	Number of encls	Number of encls with condition	Character specific rate per 100 encls	Lower 95% CI	Upper 95% CI
Total	52628	1018	1.9342	1.7119	2.1565
45-64 years	26695	261	0.9761	0.8286	1.1237
65-74 years	11961	294	2.4560	2.0503	2.8617
75+ years	13972	464	3.3181	2.8278	3.8083
Males	23178	631	2.7222	2.3848	3.0596
Females	29029	379	1.3065	1.1055	1.5075
Missing sex	421	8	1.8329	0.0644	3.6014
Male 45-64	11896	185	1.5592	1.2830	1.8354
Male 65-74	5374	187	3.4811	2.7902	4.1721
Male 75+	5908	258	4.3739	3.6665	5.0812
Female 45-64	14612	73	0.5018	0.3660	0.6375
Female 65-74	6478	104	1.6061	1.2334	1.9788
Female 75+	7938	202	2.5434	2.0473	3.0395
Missing sex or age	421	8	1.8329	0.0644	3.6014

Table 2.1.3 Patient characteristic specific rates of IHD 45+ Apr07-Mar08 wgt'd

Patient characteristics	Number of encls	Number of encls with condition	Character specific rate per 100 encls	Lower 95% CI	Upper 95% CI
New to practice	2294	21	0.9052	0.4972	1.3133
Seen previously	49484	985	1.9909	1.7613	2.2204
Missing status	850	12	1.4137	0.4813	2.3461

HCC card	28565	719	2.5182	2.1667	2.8698
No HCC card	20443	254	1.2412	1.0413	1.4412
Missing HCC	3620	45	1.2393	0.7967	1.6818

VA card	2594	91	3.5223	2.6854	4.3593
No VA card	45641	876	1.9201	1.6786	2.1617
Missing VA	4393	50	1.1431	0.7713	1.5149

NESB	5467	127	2.3321	1.7258	2.9384
English speaking background	42788	839	1.9605	1.7084	2.2126
Missing NESB status	4373	52	1.1794	0.7969	1.5619

Aboriginal and/or TSI	317	7	2.1351	0.5534	3.7169
Non-Indigenous	47960	960	2.0017	1.7622	2.2412
Missing ATSI status	4351	51	1.1758	0.7925	1.5591

ASGC - Major cities	37068	717	1.9334	1.6457	2.2210
- Non-major cities	14273	282	1.9781	1.6615	2.2947
- Unknown ASGC	81	1	0.6309	.	.
- Missing ASGC	1206	18	1.5283	0.5655	2.4910

ASGS - Major cities	37371	724	1.9373	1.6513	2.2233
- Non-major cities	13971	275	1.9684	1.6551	2.2818
- Unknown ASGS	79	1	0.6417	.	.
- Missing ASGS	1206	18	1.5283	0.5655	2.4910

Table 2.2 Age by gender of patient at encounter - New IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of sex by agegp

sex(Sex of patient)
agegp(Patient Age-group)

Frequency				
Row Pct				
Col Pct	45-64	65-74	75+	Total
Male	29.3935	14.2207	4.88918	48.5034
	60.60	29.32	10.08	
	64.91	59.85	37.96	
Female	15.8908	9.54185	7.99206	33.4247
	47.54	28.55	23.91	
	35.09	40.15	62.04	
Total	45.2843	23.7626	12.8812	81.9281

Frequency Missing = 3.9318793754

Table 3.1 Number of reasons for encounter by sex of patient - IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of numrfe by sex

numrfe(Number of reasons for encounter)
sex(Sex of patient)

Frequency			
Row Pct			
Col Pct	Male	Female	Total
1	271.871	163.809	435.68
	62.40	37.60	
	43.09	43.19	
2	248.471	119.449	367.919
	67.53	32.47	
	39.38	31.49	
3	110.608	96.0106	206.618
	53.53	46.47	
	17.53	25.31	
Total	630.949	379.268	1010.22

Frequency Missing = 7.7225786677

Table 3.2: Reasons for encounters (RFEs)- ICPC chapter - IHD 45+ Apr07-Mar08 wgt

RFE chapter	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
General & unspecified	726	40.3	71.4	64.1	78.6
Circulatory	470	26.1	46.2	39.6	52.8
Endocrine & metabolic	115	6.4	11.3	8.5	14.2
Respiratory	105	5.8	10.3	8.0	12.6
Musculoskeletal	100	5.5	9.8	7.7	11.9
Skin	82	4.6	8.1	6.1	10.1
Digestive	45	2.5	4.4	2.7	6.0
Psychological	40	2.2	3.9	2.5	5.3
Neurological	26	1.5	2.6	1.3	3.9
Urology	23	1.3	2.2	1.3	3.2
Blood	19	1.1	1.9	0.1	3.7
Ear	17	0.9	1.6	0.9	2.4
Male genital system	10	0.6	1.0	0.3	1.7
Social	9	0.5	0.9	0.3	1.5
Eye	9	0.5	0.9	0.3	1.5
Female genital system	6	0.3	0.6	0.1	1.0
.
Subtotal	1803	100.0	.	.	.
.
Total RFEs	1803	100.0	177.1	170.4	183.8

Table 3.3: Top 30 reasons for encounters (RFEs) - IHD 45+ Apr07-Mar08 wgt'd

RFE label	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
Prescription all*	372	20.7	36.6	31.1	42.0
IHD*	153	8.5	15.0	8.9	21.1
Cardiac check-up*	103	5.7	10.1	7.3	13.0
Test results*	96	5.3	9.4	7.4	11.4
Pain, chest NOS	86	4.8	8.4	6.3	10.5
General check-up*	84	4.7	8.3	6.1	10.5
Follow-up encounter unspecified cardiovascular	36	2.0	3.5	2.0	5.1
Administrative procedure NOS	35	1.9	3.4	2.2	4.6
Hypertension*	33	1.8	3.3	2.0	4.5
Diabetes*	31	1.7	3.1	1.5	4.6
Preventive immun/vacc/meds-all*	27	1.5	2.7	1.4	3.9
Shortness of breath/dyspnoea	27	1.5	2.6	1.4	3.8
Blood test NOS	26	1.4	2.5	1.4	3.7
Other referrals NEC NOS	25	1.4	2.4	0.8	4.0
Cough	19	1.1	1.9	1.0	2.8
Follow-up encounter unspecified NOS	19	1.1	1.9	0.8	2.9
Back complaint*	19	1.0	1.8	0.9	2.8
Weakness/tiredness general	17	0.9	1.7	0.7	2.7
Skin symptom/complaint, other	16	0.9	1.6	0.6	2.6
Lipid disorders*	16	0.9	1.5	0.6	2.5
Clarify/discuss patient RFE/demand NOS	15	0.8	1.4	0.6	2.3
Refer physician/specialist/clinic/hosp cardiovascular	14	0.8	1.4	0.5	2.2
Rash*	14	0.8	1.4	0.5	2.2
Blood test blood/lymph	13	0.7	1.3	0.0	3.0
Vertigo/dizziness	11	0.6	1.1	0.4	1.8
Knee symptom/complaint	11	0.6	1.1	0.4	1.8
Hip symptom/complaint	10	0.6	1.0	0.3	1.7
Shoulder symptom/complaint	9	0.5	0.9	0.3	1.5
Atrial fibrillation/flutter	9	0.5	0.9	0.0	1.9
Sleep disturbance	9	0.5	0.9	0.2	1.6
Subtotal	1354	75.1	.	.	.
Other RFEs	449	24.9	.	.	.
Total RFEs	1803	100.0	177.1	170.4	183.8

* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

Table 4.1: Number of reasons for encounter by sex of patient - New IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of numrfe by sex

numrfe(Number of reasons for encounter)
sex(Sex of patient)

Frequency			
Row Pct			
Col Pct	Male	Female	Total
1	23.3847	17.7668	41.1515
	56.83	43.17	
	48.21	53.15	
2	18.1337	9.19921	27.3329
	66.34	33.66	
	37.39	27.52	
3	6.98499	6.45865	13.4436
	51.96	48.04	
	14.40	19.32	
Total	48.5034	33.4247	81.9281

Frequency Missing = 3.9318793754

Table 4.2: Reasons for encounters (RFEs)- ICPC chapter - New IHD 45+ Apr07-Mar08 wgt'd

RFE chapter	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
General & unspecified	76	54.1	88.2	75.6	100.8
Circulatory	34	24.0	39.1	26.3	52.0
Respiratory	9	6.6	10.7	3.8	17.6
Musculoskeletal	5	3.7	6.0	1.0	10.9
Skin	3	2.2	3.7	0.0	9.2
Neurological	3	2.0	3.3	.	.
Endocrine & metabolic	3	2.0	3.2	.	.
Digestive	3	1.9	3.0	.	.
Ear	2	1.3	2.1	.	.
Psychological	1	0.8	1.4	.	.
Social	1	0.5	0.7	.	.
Female genital system	1	0.4	0.7	.	.
Blood	1	0.4	0.6	.	.
Urology	0	0.3	0.5	.	.
.
Subtotal	140	100.0	.	.	.
.
Total RFEs	140	100.0	163.1	145.6	180.7

Table 4.3: Top 30 reasons for encounters (RFEs) - New IHD 45+ Apr07-Mar08 wgt'd

RFE label	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
Pain, chest NOS	43	30.5	49.7	37.7	61.7
General check-up*	11	7.5	12.3	4.9	19.7
Test results*	9	6.4	10.5	4.1	17.0
Prescription all*	9	6.3	10.3	3.5	17.1
IHD*	8	6.0	9.9	3.4	16.3
Follow-up encounter unspecified cardiovascular	5	3.3	5.4	0.0	10.9
Shortness of breath/dyspnoea	4	3.1	5.1	0.0	10.2
Hypertension*	4	3.0	4.9	0.0	11.0
Sensation disturbance, other	3	2.0	3.3	.	.
Follow-up encounter unspecified NOS	2	1.6	2.7	.	.
Rash*	2	1.6	2.7	.	.
Cough	2	1.6	2.7	.	.
Observation/health educat/advice/diet cardiovascular	2	1.6	2.7	.	.
Arm symptom/complaint	2	1.6	2.6	.	.
Encounter/prob initiated by provider cardiovascular	2	1.5	2.4	.	.
Cardiac check-up*	2	1.2	1.9	.	.
Other preventive procedures cardiovascular	2	1.1	1.8	.	.
Swollen ankles/oedema	2	1.1	1.8	.	.
Hand/finger symptom/complaint	2	1.1	1.8	.	.
Lipid disorders*	1	1.0	1.7	.	.
Abdominal pain*	1	0.9	1.5	.	.
Weakness/tiredness general	1	0.9	1.5	.	.
Breathing problems, other	1	0.9	1.5	.	.
Gastro-oesophageal reflux disease*	1	0.9	1.5	.	.
Cardiovascular symptom/complaint, other	1	0.9	1.5	.	.
Administrative procedure NOS	1	0.8	1.4	.	.
Electrical tracings cardiovascular	1	0.8	1.3	.	.
Excessive ear wax	1	0.7	1.2	.	.
Pressure/tightness of heart	1	0.7	1.2	.	.
Osteoporosis	1	0.7	1.2	.	.
Subtotal	129	91.8	.	.	.
Other RFEs	12	8.2	.	.	.
Total RFEs	140	100.0	163.1	145.6	180.7

* Includes multiple ICD-9 or ICD-9 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

Table 5.1 Number of problems by gender of patient - IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of numprob by sex

numprob(Number of problems managed)
sex(Sex of patient)

Frequency			
Row Pct			
Col Pct	Male	Female	Total
1	148.765 64.11 23.58	83.2888 35.89 21.96	232.054
2	217.983 65.30 34.55	115.828 34.70 30.54	333.811
3	160.163 60.94 25.38	102.652 39.06 27.07	262.815
4	104.038 57.31 16.49	77.4999 42.69 20.43	181.537
Total	630.949	379.268	1010.22

Frequency Missing = 7.7225786677

Table 5.2: Other problems managed - ICPC chapter - IHD 45+ Apr07-Mar08 wgt

Problem chapter	n	% of total problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Endocrine & metabolic	310	22.0	30.5	26.4	34.5
Circulatory	295	20.9	28.9	24.6	33.3
Musculoskeletal	143	10.1	14.0	11.6	16.4
Respiratory	125	8.8	12.3	9.9	14.7
Digestive	111	7.9	10.9	8.8	12.9
Skin	101	7.2	10.0	7.9	12.1
Psychological	92	6.5	9.1	7.0	11.1
General & unspecified	83	5.9	8.1	6.2	10.0
Urology	37	2.6	3.7	2.4	4.9
Neurological	22	1.5	2.1	1.1	3.2
Male genital system	22	1.5	2.1	1.2	3.0
Eye	20	1.4	2.0	1.0	3.0
Blood	20	1.4	1.9	0.9	3.0
Ear	17	1.2	1.7	0.9	2.5
Female genital system	12	0.8	1.2	0.5	1.8
Social	2	0.2	0.2	.	.
.
Subtotal	1411	100.0	.	.	.
.
Total problems	1411	100.0	138.6	130.0	147.2

Table 5.3: Top 30 other problems managed - IHD 45+ Apr07-Mar08 wgt'd

Problem label	n	% of total other problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Hypertension*	196	13.9	19.2	15.5	22.9
Diabetes*	129	9.1	12.7	10.2	15.1
Lipid disorders*	101	7.2	10.0	7.2	12.7
Gastro-oesophageal reflux disease*	61	4.3	6.0	4.4	7.6
Osteoarthritis*	39	2.7	3.8	2.6	5.0
Chronic obstructive pulmonary disease	35	2.5	3.5	2.0	4.9
Preventive immun/vacc/meds-all*	33	2.4	3.3	2.0	4.6
Sleep disturbance	33	2.3	3.2	1.9	4.6
Depression*	27	1.9	2.6	1.7	3.6
Osteoporosis	23	1.6	2.2	1.1	3.3
Atrial fibrillation/flutter	22	1.6	2.2	1.3	3.2
Heart failure	22	1.5	2.1	1.0	3.2
Back complaint*	21	1.5	2.1	1.1	3.0
Gout	20	1.4	1.9	0.8	3.0
Malignant neoplasm of skin	19	1.3	1.8	0.8	2.8
Hypothyroidism/myxoedema	18	1.3	1.8	0.7	2.8
Solar keratosis/sunburn	17	1.2	1.7	0.8	2.6
Asthma	17	1.2	1.7	0.8	2.5
Renal impairment (all)*	16	1.1	1.6	0.8	2.4
Vitamin/nutritional deficiency	15	1.1	1.5	0.6	2.4
General check-up*	13	0.9	1.3	0.5	2.1
Prescription all*	12	0.9	1.2	0.4	2.0
Anaemia*	12	0.8	1.1	0.2	2.0
Constipation	12	0.8	1.1	0.2	2.0
Anxiety*	11	0.8	1.1	0.5	1.7
Endocrine/metabolic/nutritional disease, other	11	0.8	1.1	0.2	1.9
Cerebrovascular disease (all)*	10	0.7	0.9	0.3	1.5
Test results*	9	0.7	0.9	0.2	1.6
Fracture*	9	0.6	0.9	0.2	1.6
Glaucoma	8	0.6	0.8	0.2	1.5
.
Subtotal	970	68.7	.	.	.
.
Other problems managed	441	31.3	.	.	.
.
Total problems	1411	100.0	138.6	130.0	147.2

* Includes multiple ICD-10 or ICD-10 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

Table 6.1 Number of problems by sex of patient - New IHD 45+ Apr07-Mar08 wgt

The FREQ Procedure

Table of numprob by sex

numprob(Number of problems managed)
sex(Sex of patient)

Frequency			
Row Pct			
Col Pct	Male	Female	Total
1	24.2304	20.4403	44.6707
	54.24	45.76	
	49.96	61.15	
2	15.0062	7.7712	22.7774
	65.88	34.12	
	30.94	23.25	
3	8.19602	2.66598	10.862
	75.46	24.54	
	16.90	7.98	
4	1.07083	2.54719	3.61802
	29.60	70.40	
	2.21	7.62	
Total	48.5034	33.4247	81.9281

Frequency Missing = 3.9318793754

Table 6.2: Other problems managed - ICPC chapter - New IHD 45+ Apr07-Mar08 wgt'd

Problem chapter	n	% of total problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Circulatory	12	21.8	14.1	5.6	22.5
Endocrine & metabolic	7	13.3	8.6	2.1	15.1
Respiratory	7	11.8	7.6	1.9	13.2
Digestive	6	11.1	7.1	1.1	13.2
General & unspecified	5	9.0	5.8	0.6	11.0
Psychological	5	8.5	5.5	0.3	10.7
Skin	4	7.6	4.9	0.0	10.9
Musculoskeletal	3	5.9	3.8	0.0	8.3
Urology	2	2.9	1.9	.	.
Female genital system	1	2.3	1.5	.	.
Male genital system	1	1.9	1.2	.	.
Ear	1	1.9	1.2	.	.
Blood	1	1.4	0.9	.	.
Social	0	0.6	0.4	.	.
Subtotal	55	100.0	.	.	.
Total problems	55	100.0	.	.	.

Table 6.3: Top 30 other problems managed - New IHD 45+ Apr07-Mar08 wgt'd

Problem label	n	% of total other problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Hypertension*	11	19.1	12.3	4.1	20.5
Gastro-oesophageal reflux disease*	4	7.9	5.1	0.1	10.1
Prescription all*	3	5.6	3.6	0.0	7.9
Diabetes*	3	5.5	3.5	0.0	7.4
Asthma	2	4.2	2.7	.	.
Lipid disorders*	2	4.2	2.7	.	.
Rash*	2	4.2	2.7	.	.
Stomach function disorder	2	2.9	1.8	.	.
Gout	2	2.9	1.8	.	.
Sleep disturbance	2	2.8	1.8	.	.
Arthritis (excl. OA and rheumatoid)*	2	2.7	1.8	.	.
Congenital anomaly urinary tract	1	2.2	1.4	.	.
Tobacco abuse	1	2.1	1.4	.	.
Anxiety*	1	1.9	1.3	.	.
Neoplasm skin, benign/unspecified	1	1.9	1.2	.	.
Benign prostatic hypertrophy	1	1.9	1.2	.	.
Excessive ear wax	1	1.9	1.2	.	.
Osteoporosis	1	1.8	1.2	.	.
Cough	1	1.8	1.1	.	.
Upper respiratory infection, acute	1	1.8	1.1	.	.
Acute bronchitis/bronchiolitis	1	1.7	1.1	.	.
Test results*	1	1.7	1.1	.	.
Abnormal test results*	1	1.5	1.0	.	.
Malignant neoplasm of skin	1	1.5	1.0	.	.
General check-up*	1	1.4	0.9	.	.
Leukaemia	1	1.4	0.9	.	.
Back complaint*	1	1.4	0.9	.	.
Allergic rhinitis	1	1.4	0.9	.	.
Menopausal symptom/complaint	1	1.2	0.8	.	.
Acute stress reaction	1	1.1	0.7	.	.
.
Subtotal	52	93.7	.	.	.
Other problems managed	4	6.3	.	.	.
Total problems	55	100.0	.	.	.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

Table 7.1: Frequency of medication provision - IHD 45+ Apr07-Mar08 wgt

Data	n	Per 100	Lower	Upper	% meds for	Lower	Upper
		IHD 45+ probs	95% CI	95% CI	IHD 45+ probs	95% CI	95% CI
Medications	1216	119.5	109.9	129.1	100.0	100.0	100.0
- Prescribed	1174	115.3	105.8	124.9	96.5	95.1	98.0
- Advised OTC	23	2.2	1.1	3.4	1.9	0.9	2.8
- GP supplied	19	1.9	0.5	3.3	1.6	0.4	2.7

Table 7.2: Top 30 medications prescribed - ATC (WHO) Level 2 (3 digits) - IHD 45+ Apr07-Mar08 wgt'd

ATC label	ATC 3 digit code	n	Per 100 IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for IHD 45+		
						Lower 95% CI	Upper 95% CI	
ANTITHROMBOTIC AGENTS	B01	278	27.3	23.3	31.3	23.7	20.8	26.5
CARDIAC THERAPY	C01	263	25.8	21.9	29.7	22.4	19.2	25.5
LIPID MODIFYING AGENTS	C10	211	20.7	17.3	24.1	17.9	15.5	20.3
BETA BLOCKING AGENTS	C07	141	13.9	11.1	16.6	12.0	10.0	14.0
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	C09	137	13.4	10.8	16.0	11.7	9.7	13.6
CALCIUM CHANNEL BLOCKERS	C08	69	6.8	4.9	8.7	5.9	4.3	7.5
DIURETICS	C03	31	3.1	1.4	4.7	2.7	1.2	4.1
ANALGESICS	N02	19	1.8	0.9	2.7	1.6	0.8	2.4
PSYCHOLEPTICS	N05	4	0.4	0.0	0.8	0.3	0.0	0.7
DRUGS FOR ACID RELATED DISORDERS	A02	3	0.3	0.0	0.8	0.3	0.0	0.7
MINERAL SUPPLEMENTS	A12	2	0.2	.	.	0.2	.	.
THYROID THERAPY	H03	2	0.2	.	.	0.2	.	.
DRUGS USED IN DIABETES	A10	2	0.2	.	.	0.2	.	.
VARIOUS	V	2	0.2	.	.	0.1	.	.
CORTICOSTEROIDS FOR SYSTEMIC USE	H02	2	0.2	.	.	0.1	.	.
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	M01	1	0.1	.	.	0.1	.	.
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	R03	1	0.1	.	.	0.1	.	.
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	D07	1	0.1	.	.	0.1	.	.
ANTIGOUT PREPARATIONS	M04	1	0.1	.	.	0.1	.	.
DRUGS FOR TREATMENT OF BONE DISEASES	M05	1	0.1	.	.	0.1	.	.
PSYCHOANALEPTICS	N06	1	0.1	.	.	0.1	.	.
ALL OTHER THERAPEUTIC PRODUCTS	V03	1	0.1	.	.	0.1	.	.
ANTIANEMIC PREPARATIONS	B03	1	0.1	.	.	0.0	.	.
Subtotal		1174	.	.	.	100.0	.	.
Other Meds		0	.	.	.	0.0	.	.
Total Meds		1174	115.3	105.8	124.9	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 3 digit ATC level, but could be coded at 1 digit ATC level. Also some medications were mapped to 1 digit ATC codes, because there was not an appropriate 3 digit ATC code available at the time.

Table 7.2.1: Top 30 medications prescribed - ATC (WHO) Level 3 (4 digits) - IHD 45+ Apr07-Mar08 wgt'd

ATC label	ATC 4 digit code	n	Per 100 IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed		
						meds for IHD 45+	Lower 95% CI	Upper 95% CI
ANTITHROMBOTIC AGENTS	B01A	278	27.3	23.3	31.3	23.7	20.8	26.5
VASODILATORS USED IN CARDIAC DISEASES	C01D	241	23.7	19.9	27.5	20.5	17.4	23.7
LIPID MODIFYING AGENTS, PLAIN	C10A	203	20.0	16.6	23.4	17.3	14.9	19.7
BETA BLOCKING AGENTS	C07A	141	13.9	11.1	16.6	12.0	10.0	14.0
ACE INHIBITORS, PLAIN	C09A	105	10.3	8.0	12.6	8.9	7.1	10.7
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	C08D	38	3.7	2.4	5.1	3.2	2.1	4.3
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	C08C	24	2.3	0.8	3.8	2.0	0.7	3.3
ANGIOTENSIN II ANTAGONISTS, PLAIN	C09C	23	2.2	1.2	3.2	1.9	1.1	2.8
HIGH-CEILING DIURETICS	C03C	21	2.1	0.8	3.3	1.8	0.7	2.9
OTHER ANALGESICS AND ANTIPYRETICS	N02B	18	1.7	0.9	2.6	1.5	0.8	2.2
CARDIAC GLYCOSIDES	C01A	15	1.5	0.6	2.4	1.3	0.5	2.1
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS	C08E	8	0.8	0.2	1.4	0.7	0.2	1.2
LIPID MODIFYING AGENTS, COMBINATIONS	C10B	8	0.7	0.2	1.3	0.6	0.2	1.1
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	C09D	6	0.6	0.2	1.0	0.5	0.2	0.9
ANTIARRHYTHMICS, CLASS I AND III	C01B	6	0.6	0.1	1.0	0.5	0.1	0.9
POTASSIUM-SPARING AGENTS	C03D	6	0.6	0.0	1.1	0.5	0.0	1.0
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	A02B	3	0.3	0.0	0.8	0.3	0.0	0.7
ACE INHIBITORS, COMBINATIONS	C09B	3	0.3	0.0	0.7	0.3	0.0	0.6
LOW-CEILING DIURETICS, EXCL. THIAZIDES	C03B	3	0.2	.	.	0.2	.	.
POTASSIUM	A12B	2	0.2	.	.	0.2	.	.
THYROID PREPARATIONS	H03A	2	0.2	.	.	0.2	.	.
HYPNOTICS AND SEDATIVES	N05C	2	0.2	.	.	0.2	.	.
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	A10B	2	0.2	.	.	0.2	.	.
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	C03E	2	0.2	.	.	0.2	.	.
VARIOUS	V	2	0.2	.	.	0.1	.	.
ANXIOLYTICS	N05B	2	0.2	.	.	0.1	.	.
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	H02A	2	0.2	.	.	0.1	.	.
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS	M01A	1	0.1	.	.	0.1	.	.
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	R03B	1	0.1	.	.	0.1	.	.
CORTICOSTEROIDS, PLAIN	D07A	1	0.1	.	.	0.1	.	.
Subtotal		1168	.	.	.	99.5	.	.
Other Meds		6	.	.	.	0.5	.	.
Total Meds		1174	115.3	105.8	124.9	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 4 digit ATC level, but could be coded at 1, or 3 digit ATC level. Also some medications were mapped to 1 or 3 digit ATC codes, because there was not an appropriate 4 digit ATC code available at the time.

Table 7.2.2: Top 30 medications prescribed - ATC (WHO) Level 4 (5 digits) - IHD 45+ Apr07-Mar08 wgt'd

ATC label	ATC 5 digit code	n	Per 100 IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed		
						IHD 45+	Lower 95% CI	Upper 95% CI
Platelet aggregation inhibitors excl. heparin	B01AC	256	25.1	21.0	29.3	21.8	18.7	24.9
Organic nitrates	C01DA	211	20.7	17.4	24.1	18.0	15.2	20.8
HMG CoA reductase inhibitors	C10AA	189	18.5	15.2	21.9	16.1	13.7	18.5
Beta blocking agents, selective	C07AB	120	11.8	9.5	14.1	10.2	8.5	12.0
ACE inhibitors, plain	C09AA	105	10.3	8.0	12.6	8.9	7.1	10.7
Benzothiazepine derivatives	C08DB	32	3.1	1.8	4.4	2.7	1.7	3.8
Other vasodilators used in cardiac diseases	C01DX	30	3.0	1.7	4.3	2.6	1.5	3.7
Dihydropyridine derivatives	C08CA	24	2.3	0.8	3.8	2.0	0.7	3.3
Angiotensin II antagonists, plain	C09CA	23	2.2	1.2	3.2	1.9	1.1	2.8
Vitamin K antagonists	B01AA	22	2.1	0.9	3.4	1.9	0.7	3.0
Sulfonamides, plain	C03CA	21	2.1	0.8	3.3	1.8	0.7	2.9
Salicylic acid and derivatives	N02BA	17	1.7	0.9	2.5	1.5	0.7	2.2
Digitalis glycosides	C01AA	15	1.5	0.6	2.4	1.3	0.5	2.1
Alpha and beta blocking agents	C07AG	13	1.2	0.4	2.1	1.1	0.3	1.8
Other lipid modifying agents	C10AX	11	1.1	0.5	1.7	0.9	0.4	1.5
Beta blocking agents, non-selective	C07AA	8	0.8	0.1	1.5	0.7	0.1	1.3
Other non-selective calcium channel blockers	C08EX	8	0.8	0.2	1.4	0.7	0.2	1.2
Phenylalkylamine derivatives	C08DA	6	0.6	0.1	1.1	0.5	0.1	1.0
Angiotensin II antagonists and diuretics	C09DA	6	0.6	0.2	1.0	0.5	0.2	0.9
Aldosterone antagonists	C03DA	6	0.6	0.0	1.1	0.5	0.0	1.0
HMG CoA reductase inhibitors, other combinations	C10BX	5	0.5	0.0	1.0	0.4	0.0	0.8
Antiarrhythmics, class III	C01BD	4	0.4	0.0	0.8	0.4	0.0	0.7
Fibrates	C10AB	3	0.3	0.0	0.7	0.3	0.0	0.6
Proton pump inhibitors	A02BC	3	0.3	0.0	0.8	0.3	0.0	0.7
ACE inhibitors and diuretics	C09BA	3	0.3	0.0	0.7	0.3	0.0	0.6
Sulfonamides, plain	C03BA	3	0.2	.	.	0.2	.	.
Potassium	A12BA	2	0.2	.	.	0.2	.	.
HMG CoA reductase inhibitors in combination with other lipid modifying agents	C10BA	2	0.2	.	.	0.2	.	.
Thyroid hormones	H03AA	2	0.2	.	.	0.2	.	.
Benzodiazepine derivatives	N05CD	2	0.2	.	.	0.2	.	.
Subtotal		1153	.	.	.	98.2	.	.
Other Meds		21	.	.	.	1.8	.	.
Total Meds		1174	115.3	105.8	124.9	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 5 digit ATC code, but could be coded at 1, 3 or 4 digit ATC code. Also some medications were mapped to 1, 3 or 4 digit ATC code, because there was not an appropriate 5 digit ATC code available at the time.

Table 7.2.3: Top 60 generic medications prescribed - CAPS generic (4 digits) - IHD 45+ Apr07-Mar08 wgt

CAPS generic	CAPS 4 digit code	n	Per 100 IHD 45+ probs	Lower		% of prescribed		Upper	
				95% CI	95% CI	meds for IHD 45+	95% CI	95% CI	95% CI
Clopidogrel	B218	136	13.4	10.6	16.1	11.6	9.4	13.7	
GTN (glyceryl trinitrate)	C301	126	12.3	9.8	14.8	10.7	8.5	12.9	
Aspirin cardiovascular	B238	114	11.2	8.5	13.8	9.7	7.6	11.8	
Atorvastatin	C959	101	9.9	7.7	12.2	8.6	6.8	10.4	
Isosorbide mononitrate	C307	81	8.0	5.9	10.1	6.9	5.1	8.7	
Metoprolol	C505	66	6.5	4.8	8.3	5.6	4.2	7.1	
Simvastatin	C954	56	5.5	4.0	7.0	4.8	3.5	6.0	
Ramipril	C122	53	5.2	3.6	6.9	4.5	3.2	5.9	
Atenolol	C504	48	4.7	3.1	6.4	4.1	2.8	5.4	
Perindopril	C117	36	3.5	2.1	5.0	3.1	1.8	4.3	
Nicorandil	C308	30	3.0	1.7	4.3	2.6	1.5	3.7	
Diltiazem anti-hypertensive	C120	29	2.9	1.7	4.1	2.5	1.5	3.5	
Warfarin sodium	B204	22	2.1	0.9	3.4	1.9	0.7	3.0	
Frusemide (Furosemide)	U204	21	2.1	0.8	3.3	1.8	0.7	2.9	
Aspirin	N107	17	1.7	0.9	2.5	1.5	0.7	2.2	
Irbesartan	C128	17	1.6	0.8	2.5	1.4	0.7	2.1	
Rosuvastatin	C965	16	1.5	0.4	2.7	1.3	0.4	2.3	
Digoxin	C401	15	1.5	0.6	2.4	1.3	0.5	2.1	
Pravastatin	C956	14	1.4	0.6	2.2	1.2	0.5	1.9	
Amlodipine	C123	13	1.3	0.2	2.3	1.1	0.1	2.0	
Carvedilol	C509	13	1.2	0.4	2.1	1.1	0.3	1.8	
Ezetimibe	C962	11	1.1	0.5	1.7	0.9	0.4	1.5	
Lisinopril	C119	8	0.8	0.2	1.4	0.7	0.2	1.2	
Perhexiline	C309	8	0.8	0.2	1.4	0.7	0.2	1.2	
Sotalol	C209	6	0.6	0.0	1.2	0.5	0.0	1.1	
Verapamil hydrochloride	C114	6	0.6	0.1	1.1	0.5	0.1	1.0	
Spironolactone	U214	6	0.6	0.0	1.1	0.5	0.0	1.0	
Bisoprolol fumarate	C510	6	0.6	0.0	1.1	0.5	0.0	1.0	
Candesartan cilexetil	C130	6	0.6	0.0	1.1	0.5	0.0	1.0	
Dipyridamole/Aspirin	C920	5	0.5	0.0	1.0	0.4	0.0	0.9	
Atorvastatin/Amlodipine	C966	5	0.5	0.0	1.0	0.4	0.0	0.8	
Lercanidipine	C138	5	0.5	0.0	0.9	0.4	0.0	0.8	
Enalapril mal	C113	4	0.4	0.0	0.9	0.4	0.0	0.8	
Amiodarone hcl	C207	4	0.4	0.0	0.8	0.4	0.0	0.7	

Table 7.2.3: Top 60 generic medications prescribed - CAPS generic (4 digits) - IHD 45+ Apr07-Mar08 wgt

CAPS generic	CAPS 4 digit code	n	Per 100 IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed		
						meds for IHD 45+	Lower 95% CI	Upper 95% CI
Isosorbide dinitrate	C302	4	0.4	0.0	0.8	0.4	0.0	0.7
Nifedipine	C305	4	0.4	0.0	0.8	0.3	0.0	0.7
Omeprazole	D307	3	0.3	.	.	0.2	.	.
Irbesartan/Hydrochlorothiazide	C132	3	0.3	.	.	0.2	.	.
Fenofibrate	C963	3	0.2	.	.	0.2	.	.
Indapamide	C116	3	0.2	.	.	0.2	.	.
Potassium chloride	T202	2	0.2	.	.	0.2	.	.
Simvastatin/Ezetimibe	C964	2	0.2	.	.	0.2	.	.
Thyroxine	H402	2	0.2	.	.	0.2	.	.
Diltiazem anti-angina	C306	2	0.2	.	.	0.2	.	.
Perindopril/Indapamide	C135	2	0.2	.	.	0.2	.	.
Propranolol hydrochloride	C503	2	0.2	.	.	0.2	.	.
Felodipine	C112	2	0.2	.	.	0.2	.	.
Metformin	H308	2	0.2	.	.	0.2	.	.
Trianterene/Hydrochlorothiazide	U212	2	0.2	.	.	0.2	.	.
Flecainide acetate	C206	2	0.2	.	.	0.1	.	.
Illegible	Z000	2	0.2	.	.	0.1	.	.
Telmisartan/Hydrochlorothiazide	C141	2	0.2	.	.	0.1	.	.
Prednisolone	H203	2	0.2	.	.	0.1	.	.
Fosinopril	C118	2	0.2	.	.	0.1	.	.
Candesartan/Hydrochlorothiazide	C137	2	0.1	.	.	0.1	.	.
Tiotropium	R310	1	0.1	.	.	0.1	.	.
Allopurinol	M302	1	0.1	.	.	0.1	.	.
Betamethasone topical	S202	1	0.1	.	.	0.1	.	.
Diazepam	P201	1	0.1	.	.	0.1	.	.
Risedronate sodium	T421	1	0.1	.	.	0.1	.	.
	
Subtotal		1160	.	.	.	98.8	.	.
	
Other Meds		14	.	.	.	1.2	.	.
	
Total Meds		1174	115.3	105.8	124.9	100.0	.	.

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
Total prescribed IHD 45+ medication		1174	2.2	1.3	.	.	.
Clopidogrel		136	0.3	0.2	13.4	11.6	.
	Clopidogrel Tablets 75 mg	14	0.0	0.0	1.3	1.2	9.9
	Iscover tablets 75 mg	42	0.1	0.0	4.1	3.6	30.9
	Plavix NOS	2	0.0	0.0	0.2	0.2	1.5
	Plavix tablets 75 mg	78	0.1	0.1	7.7	6.7	57.6
GTN (glyceryl trinitrate)		126	0.2	0.1	12.3	10.7	.
	GTN (glyceryl trinitrate) NOS	5	0.0	0.0	0.5	0.4	3.7
	GTN (glyceryl trinitrate) Tablets 600 mcg	1	0.0	0.0	0.1	0.1	0.8
	GTN (glyceryl trinitrate) Sublingual 400 mcg	10	0.0	0.0	1.0	0.8	7.8
	GTN (glyceryl trinitrate) Transdermal 5 mg	1	0.0	0.0	0.1	0.1	0.9
	Transiderm Nitro NOS	1	0.0	0.0	0.1	0.1	0.8
	Transiderm Nitro patch 5 mg	16	0.0	0.0	1.5	1.3	12.6
	Transiderm Nitro patch 10 mg	6	0.0	0.0	0.6	0.5	4.9
	Anginine tablets 600 mcg	18	0.0	0.0	1.7	1.5	14.0
	Nitrolingual spray sublingual 400 mcg	52	0.1	0.1	5.1	4.5	41.7
	Nitro-dur patches 5 mg	9	0.0	0.0	0.9	0.8	7.3
	Nitro-dur patches 10 mg	4	0.0	0.0	0.4	0.4	3.5
	Nitro-dur patches 15 mg	1	0.0	0.0	0.1	0.1	0.8
	Nitradisc patches 10 mg	0	0.0	0.0	0.0	0.0	0.3
	Nitrostat tablets 600 mcg	1	0.0	0.0	0.1	0.1	1.0
Aspirin cardiovascular		114	0.2	0.1	11.2	9.7	.
	Aspirin tablets 100 mg	41	0.1	0.0	4.0	3.5	35.9
	Astrix NOS	41	0.1	0.0	4.0	3.5	36.1
	Astrix capsules 100 mg	1	0.0	0.0	0.1	0.0	0.5
	Astrix tablets 100 mg	6	0.0	0.0	0.6	0.5	5.1
	Cardiprin tablets 100 mg	5	0.0	0.0	0.5	0.4	4.2
	Cartia tablets 100 mg	21	0.0	0.0	2.0	1.8	18.2
Atorvastatin		101	0.2	0.1	9.9	8.6	.
	Atorvastatin Tablets 20 mg	0	0.0	0.0	0.0	0.0	0.4
	Atorvastatin Tablets 40 mg	2	0.0	0.0	0.2	0.2	2.1
	Atorvastatin Tablets 80 mg	1	0.0	0.0	0.1	0.1	1.2
	Lipitor NOS	1	0.0	0.0	0.1	0.1	1.4

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Lipitor tablets 10 mg	12	0.0	0.0	1.2	1.0	11.8
	Lipitor tablets 20 mg	17	0.0	0.0	1.7	1.4	16.7
	Lipitor tablets 40 mg	51	0.1	0.1	5.0	4.3	50.3
	Lipitor tablets 80 mg	16	0.0	0.0	1.6	1.4	16.2
Isosorbide mononitrate		81	0.2	0.1	8.0	6.9	.
	Isosorbide mononitrate Tablets 60 mg	2	0.0	0.0	0.2	0.2	2.5
	Isosorbide mononitrate Tablets 120 mg	1	0.0	0.0	0.1	0.1	1.1
	Duride NOS	0	0.0	0.0	0.0	0.0	0.2
	Duride tablets 60 mg	12	0.0	0.0	1.2	1.1	15.4
	Imdur NOS	3	0.0	0.0	0.3	0.3	4.2
	Monodur tablets 60 mg	7	0.0	0.0	0.6	0.6	8.1
	Imdur tablets 60 mg	30	0.1	0.0	2.9	2.5	36.7
	Monodur tablets 120 mg	11	0.0	0.0	1.0	0.9	13.0
	Imdur tablets 120 mg	15	0.0	0.0	1.5	1.3	18.7
Metoprolol		66	0.1	0.1	6.5	5.6	.
	Metoprolol NOS	2	0.0	0.0	0.2	0.2	2.7
	Metoprolol Tablets 50 mg	17	0.0	0.0	1.6	1.4	25.2
	Metoprolol Tablets 100 mg	1	0.0	0.0	0.1	0.1	2.0
	Minax tablets 50 mg	17	0.0	0.0	1.7	1.4	25.6
	Betaloc tablets 50 mg	23	0.0	0.0	2.3	2.0	35.3
	Betaloc tablets 100 mg	5	0.0	0.0	0.5	0.5	8.0
	Metoheaxal tablets 50 mg	1	0.0	0.0	0.1	0.1	1.2
Simvastatin		56	0.1	0.1	5.5	4.8	.
	Simvastatin Tablets 20 mg	4	0.0	0.0	0.4	0.3	6.7
	Simvastatin Tablets 40 mg	8	0.0	0.0	0.8	0.7	13.8
	Simvastatin Tablets 80 mg	2	0.0	0.0	0.2	0.2	4.2
	Lipex tablets 10 mg	3	0.0	0.0	0.2	0.2	4.5
	Lipex tablets 20 mg	5	0.0	0.0	0.5	0.4	8.3
	Lipex tablets 40 mg	8	0.0	0.0	0.7	0.6	13.5
	Lipex tablets 80 mg	3	0.0	0.0	0.3	0.3	5.7
	Zocor tablets 10 mg	2	0.0	0.0	0.2	0.2	3.7
	Zocor tablets 20 mg	2	0.0	0.0	0.2	0.2	3.5
	Zocor tablets 40 mg	9	0.0	0.0	0.8	0.7	15.3
	Zocor tablets 80 mg	7	0.0	0.0	0.7	0.6	12.6

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgted

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Simvabell tablets 40 mg	1	0.0	0.0	0.1	0.1	1.5
	Simvar tablets 20 mg	1	0.0	0.0	0.1	0.1	2.0
	Simvar tablets 40 mg	3	0.0	0.0	0.3	0.2	4.9
Ramipril		53	0.1	0.1	5.2	4.5	.
	Ramipril NOS	2	0.0	0.0	0.2	0.2	3.4
	Ramipril capsules 10 mg	7	0.0	0.0	0.7	0.6	13.6
	Ramipril Tablets 1.25 mg	1	0.0	0.0	0.1	0.1	2.6
	Ramipril Tablets 2.5 mg	4	0.0	0.0	0.4	0.3	7.4
	Ramipril Tablets 5 mg	9	0.0	0.0	0.9	0.8	17.4
	Tritace NOS	2	0.0	0.0	0.2	0.2	4.0
	Tritace capsules 10 mg	5	0.0	0.0	0.5	0.4	9.8
	Tritace tablets 1.25 mg	3	0.0	0.0	0.3	0.2	4.8
	Tritace tablets 2.5 mg	8	0.0	0.0	0.7	0.6	14.1
	Tritace tablets 5 mg	8	0.0	0.0	0.8	0.7	15.3
	Ramace tablets 5 mg	4	0.0	0.0	0.4	0.3	7.6
Atenolol		48	0.1	0.1	4.7	4.1	.
	Atenolol NOS	3	0.0	0.0	0.3	0.3	6.7
	Atenolol Tablets 50 mg	16	0.0	0.0	1.6	1.4	33.7
	Noten NOS	1	0.0	0.0	0.1	0.0	1.2
	Noten tablets 50 mg	24	0.0	0.0	2.4	2.0	49.6
	Tenormin tablets 50 mg	4	0.0	0.0	0.4	0.4	8.8
Perindopril		36	0.1	0.0	3.5	3.1	.
	Perindopril tablets 2.5 mg	1	0.0	0.0	0.1	0.1	4.1
	Coversyl tablets 2.5 mg	14	0.0	0.0	1.4	1.2	39.2
	Coversyl tablets 5 mg	16	0.0	0.0	1.6	1.4	45.4
	Coversyl tablets 10 mg	4	0.0	0.0	0.4	0.3	11.4
Nicorandil		30	0.1	0.0	3.0	2.6	.
	Nicorandil Tablets 10 mg	4	0.0	0.0	0.4	0.4	14.4
	Ikorel tablets 10 mg	15	0.0	0.0	1.5	1.3	50.5
	Ikorel tablets 20 mg	11	0.0	0.0	1.0	0.9	35.1
Diltiazem anti-hypertensive		29	0.1	0.0	2.9	2.5	.
	Diltiazem anti-hypertensive NOS	1	0.0	0.0	0.1	0.1	4.1
	Diltiazem anti-hypertensive Capsules 180 mg	1	0.0	0.0	0.1	0.1	3.9
	Cardizem cd anti-hypertensive capsules 180 mg	9	0.0	0.0	0.9	0.8	30.2

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgtd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Cardizem cd anti-hypertensive capsules 240 mg	7	0.0	0.0	0.7	0.6	24.6
	Cardizem cd anti-hypertensive capsules 360 mg	3	0.0	0.0	0.3	0.3	10.5
	Vasocardol cd capsules 180 mg	6	0.0	0.0	0.6	0.5	20.0
	Vasocardol cd capsules 240 mg	1	0.0	0.0	0.1	0.1	3.4
	Dilzem cd capsules 240 mg	1	0.0	0.0	0.1	0.1	3.3
Warfarin sodium		22	0.0	0.0	2.1	1.9	.
	Warfarin sodium NOS	1	0.0	0.0	0.1	0.1	3.7
	Warfarin sodium tablets 1 mg	2	0.0	0.0	0.2	0.2	11.1
	Warfarin sodium tablets 2 mg	4	0.0	0.0	0.4	0.4	19.1
	Warfarin sodium tablets 3 mg	1	0.0	0.0	0.1	0.1	4.6
	Warfarin sodium tablets 5 mg	5	0.0	0.0	0.5	0.5	24.4
	Coumadin tablets 1 mg	3	0.0	0.0	0.3	0.2	11.9
	Coumadin tablets 2 mg	3	0.0	0.0	0.3	0.3	14.9
	Marevan tablets 1 mg	1	0.0	0.0	0.1	0.1	3.5
	Coumadin tablets 5 mg	1	0.0	0.0	0.1	0.1	6.6
Frusemide (Furosemide)		21	0.0	0.0	2.1	1.8	.
	Frusemide (Furosemide) Tablets 20 mg	1	0.0	0.0	0.1	0.1	4.5
	Frusemide (Furosemide) Tablets 40 mg	4	0.0	0.0	0.4	0.4	21.3
	Uremide tablets 40 mg	4	0.0	0.0	0.4	0.4	21.3
	Urex tablets 40 mg	1	0.0	0.0	0.1	0.1	4.5
	Lasix tablets 40 mg	8	0.0	0.0	0.8	0.7	39.3
	Lasix tablets 20 mg	2	0.0	0.0	0.2	0.2	9.1
Aspirin		17	0.0	0.0	1.7	1.5	.
	Aspirin NOS	7	0.0	0.0	0.6	0.6	38.4
	Aspirin tablets 300 mg	5	0.0	0.0	0.5	0.4	27.1
	Solprin tablets 300 mg	6	0.0	0.0	0.6	0.5	34.5
Irbesartan		17	0.0	0.0	1.6	1.4	.
	Irbesartan Tablets 150 mg	2	0.0	0.0	0.2	0.1	9.8
	Avapro NOS	2	0.0	0.0	0.2	0.2	10.9
	Avapro tablets 75 mg	1	0.0	0.0	0.1	0.1	7.2
	Avapro tablets 150 mg	1	0.0	0.0	0.1	0.1	4.0
	Avapro tablets 300 mg	3	0.0	0.0	0.3	0.2	16.2
	Karvea NOS	1	0.0	0.0	0.1	0.0	3.4
	Karvea tablets 75 mg	2	0.0	0.0	0.2	0.2	10.7

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgted

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
Rosuvastatin	Karvea tablets 150 mg	2	0.0	0.0	0.2	0.1	9.3
	Karvea tablets 300 mg	5	0.0	0.0	0.5	0.4	28.6
		16	0.0	0.0	1.5	1.3	.
	Crestor tablets 5 mg	1	0.0	0.0	0.1	0.1	8.6
	Crestor tablets 10 mg	13	0.0	0.0	1.3	1.1	82.5
Digoxin	Crestor tablets 20 mg	1	0.0	0.0	0.1	0.1	8.9
		15	0.0	0.0	1.5	1.3	.
	Digoxin NOS	3	0.0	0.0	0.2	0.2	16.6
	Digoxin Tablets 62.5 mcg	4	0.0	0.0	0.4	0.4	28.5
	Lanoxin tablets 250 mcg	5	0.0	0.0	0.5	0.4	33.9
Pravastatin	Lanoxin pg tablets 62.5 mcg	3	0.0	0.0	0.3	0.3	21.0
		14	0.0	0.0	1.4	1.2	.
	Pravachol NOS	1	0.0	0.0	0.1	0.1	4.7
	Pravachol tablets 20 mg	3	0.0	0.0	0.3	0.3	21.2
	Pravachol tablets 40 mg	9	0.0	0.0	0.9	0.8	65.5
Amlodipine	Pravachol tablets 80 mg	1	0.0	0.0	0.1	0.1	8.6
		13	0.0	0.0	1.3	1.1	.
	Amlodipine tablets 5 mg	2	0.0	0.0	0.2	0.2	17.2
	Amlodipine tablets 10 mg	2	0.0	0.0	0.2	0.2	14.2
	Norvasc tablets 5 mg	4	0.0	0.0	0.4	0.3	28.2
Carvedilol	Norvasc tablets 10 mg	5	0.0	0.0	0.5	0.4	40.4
		13	0.0	0.0	1.2	1.1	.
	Carvedilol tablets 6.25 mg	1	0.0	0.0	0.1	0.1	6.7
	Dilatrend tablets 12.5 mg	9	0.0	0.0	0.9	0.8	73.9
	Dilatrend tablets 25 mg	2	0.0	0.0	0.2	0.2	19.4
Ezetimibe		11	0.0	0.0	1.1	0.9	.
	Ezetimibe tablets 10 mg	0	0.0	0.0	0.0	0.0	3.8
Lisinopril	Ezetrol tablets 10 mg	11	0.0	0.0	1.1	0.9	96.2
		8	0.0	0.0	0.8	0.7	.
	Lisinopril Tablets 10 mg	1	0.0	0.0	0.1	0.0	6.6
	Lisinopril Tablets 20 mg	0	0.0	0.0	0.0	0.0	4.7
	Prinivil tablets 5 mg	1	0.0	0.0	0.1	0.1	17.7
	Prinivil tablets 20 mg	1	0.0	0.0	0.1	0.1	17.2
	Zestril tablets 5 mg	2	0.0	0.0	0.2	0.1	20.5

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Zestril tablets 10 mg	0	0.0	0.0	0.0	0.0	5.3
	Zestril tablets 20 mg	2	0.0	0.0	0.2	0.2	28.0
Perhexiline		8	0.0	0.0	0.8	0.7	.
	Perhexiline Tablets 100 mg	5	0.0	0.0	0.5	0.4	59.3
	Pexsig tablets 100 mg	3	0.0	0.0	0.3	0.3	40.7
Sotalol		6	0.0	0.0	0.6	0.5	.
	Sotalol Tablets 160 mg	1	0.0	0.0	0.1	0.1	15.5
	Sotalol Tablets 80 mg	4	0.0	0.0	0.4	0.4	71.6
	Sotacor tablets 80 mg	1	0.0	0.0	0.1	0.1	13.0
Verapamil hydrochloride		6	0.0	0.0	0.6	0.5	.
	Verapamil hydrochloride NOS	2	0.0	0.0	0.2	0.1	25.7
	Verapamil hydrochloride tablets 40 mg	0	0.0	0.0	0.0	0.0	5.6
	Anpec tablets SR 240 mg	1	0.0	0.0	0.1	0.1	11.4
	Isoptin tablets SR 240 mg	1	0.0	0.0	0.1	0.1	15.5
	Cordilox SR tablets 180 mg	1	0.0	0.0	0.1	0.1	21.6
	Veracaps capsules SR 240 mg	1	0.0	0.0	0.1	0.1	20.3
Spiroinolactone		6	0.0	0.0	0.6	0.5	.
	Spiroinolactone Tablets 25 mg	0	0.0	0.0	0.0	0.0	6.1
	Spiractin tablets 25 mg	0	0.0	0.0	0.0	0.0	6.6
	Aldactone tablets 25 mg	5	0.0	0.0	0.5	0.4	81.1
	Aldactone tablets 100 mg	0	0.0	0.0	0.0	0.0	6.1
Bisoprolol fumarate		6	0.0	0.0	0.6	0.5	.
	Bicor NOS	1	0.0	0.0	0.1	0.0	9.8
	Bicor tablets 5 mg	3	0.0	0.0	0.3	0.2	50.7
	Bicor tablets 10 mg	2	0.0	0.0	0.2	0.2	39.5
Candesartan cilexetil		6	0.0	0.0	0.6	0.5	.
	Atacand tablets 8 mg	4	0.0	0.0	0.4	0.4	74.3
	Atacand tablets 16 mg	1	0.0	0.0	0.1	0.1	25.7
Dipyridamole/Aspirin		5	0.0	0.0	0.5	0.4	.
	Asasantin capsules 225 mg	5	0.0	0.0	0.5	0.4	100.0
Atorvastatin/Amlodipine		5	0.0	0.0	0.5	0.4	.
	Caduet tablets 45 mg	3	0.0	0.0	0.3	0.3	64.1
	Caduet tablets 50 mg	2	0.0	0.0	0.2	0.2	35.9
Lercanidipine		5	0.0	0.0	0.5	0.4	.

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Lercanidipine tablets 20 mg	1	0.0	0.0	0.1	0.1	19.0
	Zanidip tablets 10 mg	3	0.0	0.0	0.3	0.2	53.9
	Zanidip tablets 20 mg	1	0.0	0.0	0.1	0.1	27.1
Enalapril mal		4	0.0	0.0	0.4	0.4	.
	Renitec tablets 20 mg	4	0.0	0.0	0.4	0.4	100.0
Amiodarone hcl		4	0.0	0.0	0.4	0.4	.
	Amiodarone hcl tablets 200 mg	3	0.0	0.0	0.3	0.3	78.1
	Aratac tablets 100 mg	1	0.0	0.0	0.1	0.1	21.9
Isosorbide dinitrate		4	0.0	0.0	0.4	0.4	.
	Isosorbide dinitrate Tablets 10 mg	1	0.0	0.0	0.1	0.1	29.8
	Sorbidin tablets 10 mg	1	0.0	0.0	0.1	0.1	16.0
	Isordil tablets 10 mg	1	0.0	0.0	0.1	0.1	17.5
	Isordil tablets sublingual 5 mg	2	0.0	0.0	0.2	0.1	36.7
Nifedipine		4	0.0	0.0	0.4	0.3	.
	Adefin XL tablets 30 mg	1	0.0	0.0	0.1	0.1	25.1
	Adalat oros tablets 30 mg	3	0.0	0.0	0.3	0.2	66.2
	Adalat oros tablets 20 mg	0	0.0	0.0	0.0	0.0	8.7
Omeprazole		3	0.0	0.0	0.3	0.2	.
	Omeprazole NOS	1	0.0	0.0	0.1	0.1	21.5
	Losec tablets 20 mg	2	0.0	0.0	0.2	0.2	78.5
Irbesartan/Hydrochlorothiazide		3	0.0	0.0	0.3	0.2	.
	Avapro HCT tablets 162.5 mg	0	0.0	0.0	0.0	0.0	13.1
	Avapro HCT tablets 312.5 mg	1	0.0	0.0	0.1	0.1	22.8
	Karvezide tablets 162.5 mg	1	0.0	0.0	0.1	0.1	37.7
	Karvezide tablets 312.5 mg	1	0.0	0.0	0.1	0.1	26.3
Fenofibrate		3	0.0	0.0	0.2	0.2	.
	Fenofibrate NOS	2	0.0	0.0	0.1	0.1	59.5
	Lipidil tablets 145 mg	1	0.0	0.0	0.1	0.1	40.5
Indapamide		3	0.0	0.0	0.2	0.2	.
	Indapamide tablets 1.5 mg	1	0.0	0.0	0.1	0.1	40.8
	Natrilix tablets SR 1.5 mg	1	0.0	0.0	0.1	0.1	59.2
Potassium chloride		2	0.0	0.0	0.2	0.2	.
	Slow-K tablets 600 mg	2	0.0	0.0	0.2	0.2	100.0
Simvastatin/Ezetimibe		2	0.0	0.0	0.2	0.2	.

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Vytorin tablets 50 mg	2	0.0	0.0	0.2	0.2	81.0
	Vytorin tablets 90 mg	0	0.0	0.0	0.0	0.0	19.0
Thyroxine		2	0.0	0.0	0.2	0.2	.
	Oroxine tablets 100 mcg	2	0.0	0.0	0.2	0.2	100.0
Diltiazem anti-angina		2	0.0	0.0	0.2	0.2	.
	Diltiazem anti-angina Tablets 60 mg	2	0.0	0.0	0.2	0.2	100.0
Perindopril/Indapamide		2	0.0	0.0	0.2	0.2	.
	Coversyl Plus tablets 5.25 mg	2	0.0	0.0	0.2	0.2	100.0
Propranolol hydrochloride		2	0.0	0.0	0.2	0.2	.
	Inderal NOS	1	0.0	0.0	0.1	0.1	29.5
	Inderal tablets 40 mg	2	0.0	0.0	0.1	0.1	70.5
Felodipine		2	0.0	0.0	0.2	0.2	.
	Felodur tablets 2.5 mg	1	0.0	0.0	0.1	0.1	48.5
	Felodur tablets 10 mg	1	0.0	0.0	0.1	0.1	51.5
Metformin		2	0.0	0.0	0.2	0.2	.
	Metformin Tablets 500 mg	1	0.0	0.0	0.1	0.1	40.5
	Metformin tablets 1 g	1	0.0	0.0	0.1	0.1	40.5
	Diabex tablets 500 mg	0	0.0	0.0	0.0	0.0	19.0
Trianterene/Hydrochlorothiazide		2	0.0	0.0	0.2	0.2	.
	Hydrene tablets 75 mg	2	0.0	0.0	0.2	0.2	100.0
Flecainide acetate		2	0.0	0.0	0.2	0.1	.
	Flecainide acetate Tablets 100 mg	1	0.0	0.0	0.1	0.1	60.3
	Tambocor tablets 50 mg	1	0.0	0.0	0.1	0.1	39.7
Illegible		2	0.0	0.0	0.2	0.1	.
	Illegible	2	0.0	0.0	0.2	0.1	100.0
Telmisartan/Hydrochlorothiazide		2	0.0	0.0	0.2	0.1	.
	Micardis plus 80/12.5 tablets 92.5 mg	2	0.0	0.0	0.2	0.1	100.0
Prednisolone		2	0.0	0.0	0.2	0.1	.
	Prednisolone NOS	2	0.0	0.0	0.2	0.1	100.0
Fosinopril		2	0.0	0.0	0.2	0.1	.
	Monopril tablets 10 mg	1	0.0	0.0	0.1	0.1	61.2
	Monopril tablets 20 mg	1	0.0	0.0	0.1	0.1	38.8
Candesartan/Hydrochlorothiazide		2	0.0	0.0	0.1	0.1	.
	Atacand plus tablets 28.5 mg	2	0.0	0.0	0.1	0.1	100.0

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
Tiotropium		1	0.0	0.0	0.1	0.1	.
	Spiriva powder resp 18 mcg	1	0.0	0.0	0.1	0.1	100.0
Allopurinol		1	0.0	0.0	0.1	0.1	.
	Allopurinol NOS	1	0.0	0.0	0.1	0.1	100.0
Betamethasone topical		1	0.0	0.0	0.1	0.1	.
	Celestone M cream/ointment 0.2 mg 1 g	1	0.0	0.0	0.1	0.1	100.0
Diazepam		1	0.0	0.0	0.1	0.1	.
	Antenex tablets 5 mg	0	0.0	0.0	0.0	0.0	25.4
	Valium NOS	1	0.0	0.0	0.1	0.1	74.6
Risedronate sodium		1	0.0	0.0	0.1	0.1	.
	Actonel NOS	1	0.0	0.0	0.1	0.1	100.0
Dipyridamole		1	0.0	0.0	0.1	0.1	.
	Persantin NOS	1	0.0	0.0	0.1	0.1	100.0
Lumiracoxib		1	0.0	0.0	0.1	0.1	.
	Prexige NOS	1	0.0	0.0	0.1	0.1	100.0
Fosinopril/Hydrochlorothiazide		1	0.0	0.0	0.1	0.1	.
	Monoplus 10/12.5 tablets 22.5 mg	1	0.0	0.0	0.1	0.1	100.0
Fluvastatin		1	0.0	0.0	0.1	0.1	.
	Lescol xl capsules 80 mg	1	0.0	0.0	0.1	0.1	100.0
Temazepam		1	0.0	0.0	0.1	0.1	.
	Temaze NOS	1	0.0	0.0	0.1	0.1	100.0
Sumatriptan		1	0.0	0.0	0.1	0.1	.
	Imigran NOS	1	0.0	0.0	0.1	0.1	100.0
Amitriptyline		1	0.0	0.0	0.1	0.1	.
	Endep tablets 25 mg	1	0.0	0.0	0.1	0.1	100.0
Nitrazepam		1	0.0	0.0	0.1	0.1	.
	Nitrazepam Tablets 5 mg	1	0.0	0.0	0.1	0.1	100.0
Gemfibrozil		1	0.0	0.0	0.1	0.1	.
	Jezil tablets 600 mg	1	0.0	0.0	0.1	0.1	100.0
Captopril		1	0.0	0.0	0.1	0.1	.
	Acenorm tablets 25 mg	1	0.0	0.0	0.1	0.1	100.0
Quinapril		1	0.0	0.0	0.1	0.1	.
	Accupril tablets 10 mg	1	0.0	0.0	0.1	0.1	100.0
Oxygen		1	0.0	0.0	0.1	0.1	.

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD 45+ Apr07-Mar08 wgted

Generic	Product	n	% of total prescribed meds	per 100 total probs	per 100 IHD 45+ probs	% of prescribed meds for IHD 45+ probs	% of generic
	Oxygen	1	0.0	0.0	0.1	0.1	100.0
Folic acid		1	0.0	0.0	0.1	0.0	.
	Megafof tablets 500 mcg	1	0.0	0.0	0.1	0.0	100.0
Paracetamol		0	0.0	0.0	0.0	0.0	.
	Paracetamol Tablets 500 mg	0	0.0	0.0	0.0	0.0	100.0
Telmisartan		0	0.0	0.0	0.0	0.0	.
	Micardis tablets 40 mg	0	0.0	0.0	0.0	0.0	100.0
Lansoprazole		0	0.0	0.0	0.0	0.0	.
	Zoton NOS	0	0.0	0.0	0.0	0.0	100.0
Meloxicam		0	0.0	0.0	0.0	0.0	.
	Movalis tablets 15 mg	0	0.0	0.0	0.0	0.0	100.0
Alprazolam		0	0.0	0.0	0.0	0.0	.
	Xanax tablets 2 mg	0	0.0	0.0	0.0	0.0	100.0

Table 7.2.5.1: Top 60 brands of prescribed medications in alphabetic order
- IHD 45+ Apr07-Mar08 wgt

brand	n	% of prescribed meds for IHD 45+ probs	per 100 IHD 45+ probs	% of total prescribed meds	per 100 total probs
Aldactone	5	0.4	0.5	0.0	0.0
Amlodipine	4	0.3	0.4	0.0	0.0
Anginine	18	1.5	1.7	0.0	0.0
Asasantin	5	0.4	0.5	0.0	0.0
Aspirin	52	4.4	5.1	0.1	0.1
Astrix	47	4.0	4.7	0.1	0.1
Atacand	6	0.5	0.6	0.0	0.0
Atenolol	20	1.7	1.9	0.0	0.0
Avapro	6	0.5	0.6	0.0	0.0
Betaloc	29	2.4	2.8	0.1	0.0
Bicor	6	0.5	0.6	0.0	0.0
Caduet	5	0.4	0.5	0.0	0.0
Cardiprin	5	0.4	0.5	0.0	0.0
Cardizem cd anti-hypertensive	19	1.6	1.9	0.0	0.0
Cartia	21	1.8	2.0	0.0	0.0
Clopidogrel	14	1.2	1.3	0.0	0.0
Coumadin	7	0.6	0.7	0.0	0.0
Coversyl	35	2.9	3.4	0.1	0.0
Crestor	16	1.3	1.5	0.0	0.0
Digoxin	7	0.6	0.7	0.0	0.0
Dilatrend	12	1.0	1.1	0.0	0.0
Duride	13	1.1	1.2	0.0	0.0
Ezetrol	11	0.9	1.1	0.0	0.0
Fruzemide (Furosemide)	5	0.5	0.5	0.0	0.0
GTN (glyceryl trinitrate)	17	1.4	1.6	0.0	0.0
Ikorel	26	2.2	2.5	0.0	0.0
Imdur	48	4.1	4.8	0.1	0.1
Iscover	42	3.6	4.1	0.1	0.0
Karvea	9	0.7	0.8	0.0	0.0
Lanoxin	8	0.7	0.8	0.0	0.0
Lasix	10	0.9	1.0	0.0	0.0
Lipex	18	1.5	1.8	0.0	0.0
Lipitor	98	8.3	9.6	0.2	0.1

Table 7.2.5.1: Top 60 brands of prescribed medications in alphabetic order
- IHD 45+ Apr07-Mar08 wgt

brand	n	% of prescribed meds for IHD 45+ probs	per 100 IHD 45+ probs	% of total prescribed meds	per 100 total probs
Metoprolol	20	1.7	2.0	0.0	0.0
Minax	17	1.4	1.7	0.0	0.0
Monodur	17	1.5	1.7	0.0	0.0
Nicorandil	4	0.4	0.4	0.0	0.0
Nitro-dur	15	1.2	1.4	0.0	0.0
Nitrolingual	52	4.5	5.1	0.1	0.1
Norvasc	9	0.7	0.9	0.0	0.0
Noten	25	2.1	2.4	0.0	0.0
Perhexiline	5	0.4	0.5	0.0	0.0
Plavix	80	6.9	7.9	0.2	0.1
Pravachol	14	1.2	1.4	0.0	0.0
Ramace	4	0.3	0.4	0.0	0.0
Ramipril	24	2.0	2.3	0.0	0.0
Renitec	4	0.4	0.4	0.0	0.0
Simvar	4	0.3	0.4	0.0	0.0
Simvastatin	14	1.2	1.4	0.0	0.0
Solprin	6	0.5	0.6	0.0	0.0
Sotalol	5	0.5	0.5	0.0	0.0
Tenormin	4	0.4	0.4	0.0	0.0
Transiderm Nitro	23	1.9	2.2	0.0	0.0
Tritace	26	2.2	2.5	0.0	0.0
Uremide	4	0.4	0.4	0.0	0.0
Vasocardol	7	0.6	0.7	0.0	0.0
Warfarin sodium	14	1.2	1.4	0.0	0.0
Zanidip	4	0.3	0.4	0.0	0.0
Zestril	4	0.4	0.4	0.0	0.0
Zocor	20	1.7	1.9	0.0	0.0
.
Subtotal	1066	90.8	104.7	2.0	1.2
.
Other Meds	108	9.2	10.6	0.2	0.1
.
Total Meds	1174	100.0	115.3	2.2	1.3

Table 7.2.5.2: Top 60 brands of prescribed medications in descending frequency order
- IHD 45+ Apr07-Mar08 wgt

brand	n	% of prescribed meds for IHD 45+	per 100 IHD 45+	% of total prescribed meds	per 100 total problems
Lipitor	98	8.3	9.6	0.2	0.1
Plavix	80	6.9	7.9	0.2	0.1
Nitrolingual	52	4.5	5.1	0.1	0.1
Aspirin	52	4.4	5.1	0.1	0.1
Imdur	48	4.1	4.8	0.1	0.1
Astrix	47	4.0	4.7	0.1	0.1
Iscover	42	3.6	4.1	0.1	0.0
Coversyl	35	2.9	3.4	0.1	0.0
Betaloc	29	2.4	2.8	0.1	0.0
Ikorel	26	2.2	2.5	0.0	0.0
Tritace	26	2.2	2.5	0.0	0.0
Noten	25	2.1	2.4	0.0	0.0
Ramipril	24	2.0	2.3	0.0	0.0
Transiderm Nitro	23	1.9	2.2	0.0	0.0
Cartia	21	1.8	2.0	0.0	0.0
Metoprolol	20	1.7	2.0	0.0	0.0
Zocor	20	1.7	1.9	0.0	0.0
Atenolol	20	1.7	1.9	0.0	0.0
Cardizem cd anti-hypertensive	19	1.6	1.9	0.0	0.0
Lipex	18	1.5	1.8	0.0	0.0
Anginine	18	1.5	1.7	0.0	0.0
Monodur	17	1.5	1.7	0.0	0.0
Minax	17	1.4	1.7	0.0	0.0
GTN (glyceryl trinitrate)	17	1.4	1.6	0.0	0.0
Crestor	16	1.3	1.5	0.0	0.0
Nitro-dur	15	1.2	1.4	0.0	0.0
Pravachol	14	1.2	1.4	0.0	0.0
Simvastatin	14	1.2	1.4	0.0	0.0
Warfarin sodium	14	1.2	1.4	0.0	0.0
Clopidogrel	14	1.2	1.3	0.0	0.0
Duride	13	1.1	1.2	0.0	0.0
Dilatrend	12	1.0	1.1	0.0	0.0
Ezetrol	11	0.9	1.1	0.0	0.0

Table 7.2.5.2: Top 60 brands of prescribed medications in descending frequency order
- IHD 45+ Apr07-Mar08 wgted

brand	n	% of prescribed meds for IHD 45+	per 100 IHD 45+	% of total prescribed meds	per 100 total problems
Lasix	10	0.9	1.0	0.0	0.0
Norvasc	9	0.7	0.9	0.0	0.0
Karvea	9	0.7	0.8	0.0	0.0
Lanoxin	8	0.7	0.8	0.0	0.0
Coumadin	7	0.6	0.7	0.0	0.0
Vasocardol	7	0.6	0.7	0.0	0.0
Digoxin	7	0.6	0.7	0.0	0.0
Avapro	6	0.5	0.6	0.0	0.0
Solprin	6	0.5	0.6	0.0	0.0
Bicor	6	0.5	0.6	0.0	0.0
Atacand	6	0.5	0.6	0.0	0.0
Frusemide (Furosemide)	5	0.5	0.5	0.0	0.0
Sotalol	5	0.5	0.5	0.0	0.0
Asasantin	5	0.4	0.5	0.0	0.0
Caduet	5	0.4	0.5	0.0	0.0
Aldactone	5	0.4	0.5	0.0	0.0
Cardiprin	5	0.4	0.5	0.0	0.0
Perhexiline	5	0.4	0.5	0.0	0.0
Uremide	4	0.4	0.4	0.0	0.0
Renitec	4	0.4	0.4	0.0	0.0
Nicorandil	4	0.4	0.4	0.0	0.0
Zestril	4	0.4	0.4	0.0	0.0
Tenormin	4	0.4	0.4	0.0	0.0
Ramace	4	0.3	0.4	0.0	0.0
Amlodipine	4	0.3	0.4	0.0	0.0
Zanidip	4	0.3	0.4	0.0	0.0
Simvar	4	0.3	0.4	0.0	0.0
.
Subtotal	1066	90.8	104.7	2.0	1.2
.
Other Meds	108	9.2	10.6	0.2	0.1
.
Total Meds	1174	100.0	115.3	2.2	1.3

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Total IHD 45+ medications		1216	2.0	1.4	119.5	.	.
Clopidogrel		136	0.2	0.2	13.4	11.2	.
	Clopidogrel Tablets 75 mg	14	0.0	0.0	1.3	1.1	9.9
	Iscover tablets 75 mg	42	0.1	0.0	4.1	3.5	30.8
	Plavix NOS	2	0.0	0.0	0.2	0.2	1.5
	Plavix tablets 75 mg	79	0.1	0.1	7.7	6.5	57.8
GTN (glyceryl trinitrate)		129	0.2	0.1	12.7	10.6	.
	GTN (glyceryl trinitrate) NOS	5	0.0	0.0	0.5	0.4	3.6
	GTN (glyceryl trinitrate) Tablets 600 mcg	1	0.0	0.0	0.1	0.1	0.8
	GTN (glyceryl trinitrate) Sublingual 400 mcg	10	0.0	0.0	1.0	0.9	8.0
	GTN (glyceryl trinitrate) Transdermal 5 mg	1	0.0	0.0	0.1	0.1	0.8
	Transiderm Nitro NOS	1	0.0	0.0	0.1	0.1	0.7
	Transiderm Nitro patch 5 mg	16	0.0	0.0	1.6	1.3	12.5
	Transiderm Nitro patch 10 mg	6	0.0	0.0	0.6	0.5	4.7
	Anginine tablets 600 mcg	18	0.0	0.0	1.8	1.5	14.2
	Nitrolingual spray sublingual 400 mcg	53	0.1	0.1	5.3	4.4	41.3
	Nitro-dur patches 5 mg	9	0.0	0.0	0.9	0.8	7.1
	Nitro-dur patches 10 mg	4	0.0	0.0	0.4	0.4	3.4
	Nitro-dur patches 15 mg	2	0.0	0.0	0.2	0.2	1.6
	Nitradisc patches 10 mg	0	0.0	0.0	0.0	0.0	0.3
	Nitrostat tablets 600 mcg	1	0.0	0.0	0.1	0.1	1.0
Aspirin cardiovascular		129	0.2	0.1	12.7	10.6	.
	Aspirin tablets 100 mg	44	0.1	0.0	4.3	3.6	33.7
	Astrix NOS	45	0.1	0.1	4.4	3.7	34.5
	Astrix capsules 100 mg	1	0.0	0.0	0.1	0.0	0.4
	Astrix tablets 100 mg	7	0.0	0.0	0.7	0.6	5.2
	Cardiprin tablets 100 mg	8	0.0	0.0	0.8	0.6	6.0
	Cartia tablets 100 mg	26	0.0	0.0	2.6	2.1	20.2
Atorvastatin		103	0.2	0.1	10.1	8.5	.
	Atorvastatin Tablets 20 mg	0	0.0	0.0	0.0	0.0	0.4
	Atorvastatin Tablets 40 mg	3	0.0	0.0	0.2	0.2	2.4
	Atorvastatin Tablets 80 mg	1	0.0	0.0	0.1	0.1	1.1

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
	Lipitor NOS	1	0.0	0.0	0.1	0.1	1.4
	Lipitor tablets 10 mg	12	0.0	0.0	1.2	1.0	11.6
	Lipitor tablets 20 mg	18	0.0	0.0	1.8	1.5	17.6
	Lipitor tablets 40 mg	51	0.1	0.1	5.0	4.2	49.5
	Lipitor tablets 80 mg	16	0.0	0.0	1.6	1.4	16.0
Isosorbide mononitrate		81	0.1	0.1	8.0	6.7	.
	Isosorbide mononitrate Tablets 60 mg	2	0.0	0.0	0.2	0.2	2.5
	Isosorbide mononitrate Tablets 120 mg	1	0.0	0.0	0.1	0.1	1.1
	Duride NOS	0	0.0	0.0	0.0	0.0	0.2
	Duride tablets 60 mg	12	0.0	0.0	1.2	1.0	15.4
	Imdur NOS	3	0.0	0.0	0.3	0.3	4.2
	Monodur tablets 60 mg	7	0.0	0.0	0.6	0.5	8.1
	Imdur tablets 60 mg	30	0.0	0.0	2.9	2.5	36.7
	Monodur tablets 120 mg	11	0.0	0.0	1.0	0.9	13.0
	Imdur tablets 120 mg	15	0.0	0.0	1.5	1.2	18.7
Metoprolol		69	0.1	0.1	6.8	5.7	.
	Metoprolol NOS	2	0.0	0.0	0.2	0.1	2.6
	Metoprolol Tablets 50 mg	18	0.0	0.0	1.8	1.5	26.3
	Metoprolol Tablets 100 mg	1	0.0	0.0	0.1	0.1	2.0
	Minax tablets 50 mg	17	0.0	0.0	1.7	1.4	24.4
	Minax tablets 100 mg	1	0.0	0.0	0.1	0.1	1.6
	Betaloc tablets 50 mg	24	0.0	0.0	2.3	2.0	34.4
	Betaloc tablets 100 mg	5	0.0	0.0	0.5	0.4	7.7
	Metoheal tablets 50 mg	1	0.0	0.0	0.1	0.1	1.1
Simvastatin		56	0.1	0.1	5.5	4.6	.
	Simvastatin Tablets 20 mg	4	0.0	0.0	0.4	0.3	6.7
	Simvastatin Tablets 40 mg	8	0.0	0.0	0.8	0.6	13.8
	Simvastatin Tablets 80 mg	2	0.0	0.0	0.2	0.2	4.2
	Lipex tablets 10 mg	3	0.0	0.0	0.2	0.2	4.5
	Lipex tablets 20 mg	5	0.0	0.0	0.5	0.4	8.3
	Lipex tablets 40 mg	8	0.0	0.0	0.7	0.6	13.5
	Lipex tablets 80 mg	3	0.0	0.0	0.3	0.3	5.7
	Zocor tablets 10 mg	2	0.0	0.0	0.2	0.2	3.7

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
	Zocor tablets 20 mg	2	0.0	0.0	0.2	0.2	3.5
	Zocor tablets 40 mg	9	0.0	0.0	0.8	0.7	15.3
	Zocor tablets 80 mg	7	0.0	0.0	0.7	0.6	12.6
	Simvabell tablets 40 mg	1	0.0	0.0	0.1	0.1	1.5
	Simvar tablets 20 mg	1	0.0	0.0	0.1	0.1	2.0
	Simvar tablets 40 mg	3	0.0	0.0	0.3	0.2	4.9
Ramipril		54	0.1	0.1	5.3	4.5	.
	Ramipril NOS	2	0.0	0.0	0.2	0.2	3.4
	Ramipril capsules 10 mg	7	0.0	0.0	0.7	0.6	13.4
	Ramipril Tablets 1.25 mg	1	0.0	0.0	0.1	0.1	2.5
	Ramipril Tablets 2.5 mg	4	0.0	0.0	0.4	0.3	7.3
	Ramipril Tablets 5 mg	9	0.0	0.0	0.9	0.8	17.1
	Tritace NOS	3	0.0	0.0	0.3	0.2	4.7
	Tritace capsules 10 mg	5	0.0	0.0	0.5	0.4	9.6
	Tritace tablets 1.25 mg	3	0.0	0.0	0.3	0.2	4.8
	Tritace tablets 2.5 mg	8	0.0	0.0	0.8	0.7	14.7
	Tritace tablets 5 mg	8	0.0	0.0	0.8	0.7	15.1
	Ramace tablets 5 mg	4	0.0	0.0	0.4	0.3	7.5
Atenolol		48	0.1	0.1	4.7	4.0	.
	Atenolol NOS	3	0.0	0.0	0.3	0.3	6.7
	Atenolol Tablets 50 mg	16	0.0	0.0	1.6	1.3	33.7
	Noten NOS	1	0.0	0.0	0.1	0.0	1.2
	Noten tablets 50 mg	24	0.0	0.0	2.4	2.0	49.6
	Tenormin tablets 50 mg	4	0.0	0.0	0.4	0.3	8.8
Perindopril		36	0.1	0.0	3.5	3.0	.
	Perindopril tablets 2.5 mg	1	0.0	0.0	0.1	0.1	4.1
	Coversyl tablets 2.5 mg	14	0.0	0.0	1.4	1.2	39.2
	Coversyl tablets 5 mg	16	0.0	0.0	1.6	1.3	45.4
	Coversyl tablets 10 mg	4	0.0	0.0	0.4	0.3	11.4
Nicorandil		30	0.1	0.0	3.0	2.5	.
	Nicorandil Tablets 10 mg	4	0.0	0.0	0.4	0.4	14.4
	Ikorel tablets 10 mg	15	0.0	0.0	1.5	1.3	50.5
	Ikorel tablets 20 mg	11	0.0	0.0	1.0	0.9	35.1

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgt'd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Diltiazem anti-hypertensive		30	0.0	0.0	2.9	2.5	.
	Diltiazem anti-hypertensive NOS	1	0.0	0.0	0.1	0.1	4.1
	Diltiazem anti-hypertensive Capsules 180 mg	1	0.0	0.0	0.1	0.1	3.9
	Cardizem cd anti-hypertensive capsules 180 mg	9	0.0	0.0	0.9	0.8	31.2
	Cardizem cd anti-hypertensive capsules 240 mg	7	0.0	0.0	0.7	0.6	24.2
	Cardizem cd anti-hypertensive capsules 360 mg	3	0.0	0.0	0.3	0.3	10.3
	Vasocardol cd capsules 180 mg	6	0.0	0.0	0.6	0.5	19.7
	Vasocardol cd capsules 240 mg	1	0.0	0.0	0.1	0.1	3.4
Aspirin	Dilzem cd capsules 240 mg	1	0.0	0.0	0.1	0.1	3.2
		23	0.0	0.0	2.2	1.9	.
	Aspirin NOS	9	0.0	0.0	0.9	0.7	39.5
	Aspirin tablets 300 mg	7	0.0	0.0	0.7	0.6	30.9
	Solprin tablets 300 mg	6	0.0	0.0	0.6	0.5	26.3
Warfarin sodium	Aspro clear tablets 300 mg	1	0.0	0.0	0.1	0.1	3.3
		22	0.0	0.0	2.1	1.8	.
	Warfarin sodium NOS	1	0.0	0.0	0.1	0.1	3.7
	Warfarin sodium tablets 1 mg	2	0.0	0.0	0.2	0.2	11.1
	Warfarin sodium tablets 2 mg	4	0.0	0.0	0.4	0.3	19.1
	Warfarin sodium tablets 3 mg	1	0.0	0.0	0.1	0.1	4.6
	Warfarin sodium tablets 5 mg	5	0.0	0.0	0.5	0.4	24.4
	Coumadin tablets 1 mg	3	0.0	0.0	0.3	0.2	11.9
	Coumadin tablets 2 mg	3	0.0	0.0	0.3	0.3	14.9
	Marevan tablets 1 mg	1	0.0	0.0	0.1	0.1	3.5
	Coumadin tablets 5 mg	1	0.0	0.0	0.1	0.1	6.6
Frusemide (Furosemide)		22	0.0	0.0	2.1	1.8	.
	Frusemide (Furosemide) Tablets 20 mg	1	0.0	0.0	0.1	0.1	4.4
	Frusemide (Furosemide) Tablets 40 mg	4	0.0	0.0	0.4	0.4	20.9
	Uremide tablets 40 mg	4	0.0	0.0	0.4	0.4	20.9
	Urex tablets 40 mg	1	0.0	0.0	0.1	0.1	4.4
	Lasix tablets 40 mg	8	0.0	0.0	0.8	0.7	38.5
	Lasix tablets 20 mg	2	0.0	0.0	0.2	0.2	10.8
Irbesartan		17	0.0	0.0	1.7	1.4	.
	Irbesartan Tablets 150 mg	2	0.0	0.0	0.2	0.1	9.6

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
	Avapro NOS	2	0.0	0.0	0.2	0.1	10.7
	Avapro tablets 75 mg	1	0.0	0.0	0.1	0.1	7.0
	Avapro tablets 150 mg	1	0.0	0.0	0.1	0.1	3.9
	Avapro tablets 300 mg	3	0.0	0.0	0.3	0.2	15.8
	Karvea NOS	1	0.0	0.0	0.1	0.0	3.3
	Karvea tablets 75 mg	2	0.0	0.0	0.2	0.1	10.4
	Karvea tablets 150 mg	2	0.0	0.0	0.2	0.2	11.5
	Karvea tablets 300 mg	5	0.0	0.0	0.5	0.4	27.9
Rosuvastatin		16	0.0	0.0	1.6	1.3	.
	Crestor tablets 5 mg	1	0.0	0.0	0.1	0.1	8.2
	Crestor tablets 10 mg	14	0.0	0.0	1.3	1.1	83.2
	Crestor tablets 20 mg	1	0.0	0.0	0.1	0.1	8.6
Digoxin		15	0.0	0.0	1.5	1.3	.
	Digoxin NOS	3	0.0	0.0	0.2	0.2	16.6
	Digoxin Tablets 62.5 mcg	4	0.0	0.0	0.4	0.4	28.5
	Lanoxin tablets 250 mcg	5	0.0	0.0	0.5	0.4	33.9
	Lanoxin pg tablets 62.5 mcg	3	0.0	0.0	0.3	0.3	21.0
Pravastatin		14	0.0	0.0	1.4	1.2	.
	Pravachol NOS	1	0.0	0.0	0.1	0.1	4.7
	Pravachol tablets 20 mg	3	0.0	0.0	0.3	0.2	21.2
	Pravachol tablets 40 mg	9	0.0	0.0	0.9	0.8	65.5
	Pravachol tablets 80 mg	1	0.0	0.0	0.1	0.1	8.6
Amlodipine		13	0.0	0.0	1.3	1.1	.
	Amlodipine tablets 5 mg	2	0.0	0.0	0.2	0.2	17.2
	Amlodipine tablets 10 mg	2	0.0	0.0	0.2	0.1	14.2
	Norvasc tablets 5 mg	4	0.0	0.0	0.4	0.3	28.2
	Norvasc tablets 10 mg	5	0.0	0.0	0.5	0.4	40.4
Carvedilol		13	0.0	0.0	1.2	1.0	.
	Carvedilol tablets 6.25 mg	1	0.0	0.0	0.1	0.1	6.7
	Dilatrend tablets 12.5 mg	9	0.0	0.0	0.9	0.8	73.9
	Dilatrend tablets 25 mg	2	0.0	0.0	0.2	0.2	19.4
Ezetimibe		11	0.0	0.0	1.1	0.9	.
	Ezetimibe tablets 10 mg	0	0.0	0.0	0.0	0.0	3.8

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Lisinopril	Ezetrol tablets 10 mg	11	0.0	0.0	1.1	0.9	96.2
	Lisinopril Tablets 10 mg	8	0.0	0.0	0.8	0.7	.
	Lisinopril Tablets 20 mg	1	0.0	0.0	0.1	0.0	6.6
	Prinivil tablets 5 mg	0	0.0	0.0	0.0	0.0	4.7
	Prinivil tablets 20 mg	1	0.0	0.0	0.1	0.1	17.7
	Zestril tablets 5 mg	1	0.0	0.0	0.1	0.1	17.2
	Zestril tablets 10 mg	2	0.0	0.0	0.2	0.1	20.5
	Zestril tablets 20 mg	0	0.0	0.0	0.0	0.0	5.3
Perhexiline	Perhexiline Tablets 100 mg	2	0.0	0.0	0.2	0.2	28.0
	Pexsig tablets 100 mg	8	0.0	0.0	0.8	0.7	.
	Sotalol Tablets 160 mg	5	0.0	0.0	0.5	0.4	59.3
Sotalol	Sotalol Tablets 80 mg	3	0.0	0.0	0.3	0.3	40.7
	Sotacor tablets 80 mg	6	0.0	0.0	0.6	0.5	.
	Sotalol Tablets 80 mg	1	0.0	0.0	0.1	0.1	15.5
	Sotalol Tablets 160 mg	4	0.0	0.0	0.4	0.4	71.6
Verapamil hydrochloride	Sotacor tablets 80 mg	1	0.0	0.0	0.1	0.1	13.0
	Verapamil hydrochloride NOS	6	0.0	0.0	0.6	0.5	.
	Verapamil hydrochloride tablets 40 mg	2	0.0	0.0	0.2	0.1	25.7
	Anpec tablets SR 240 mg	0	0.0	0.0	0.0	0.0	5.6
	Isoptin tablets SR 240 mg	1	0.0	0.0	0.1	0.1	11.4
	Cordilox SR tablets 180 mg	1	0.0	0.0	0.1	0.1	15.5
	Veracaps capsules SR 240 mg	1	0.0	0.0	0.1	0.1	21.6
	Verapamil hydrochloride NOS	1	0.0	0.0	0.1	0.1	20.3
Spironolactone	Spironolactone Tablets 25 mg	6	0.0	0.0	0.6	0.5	.
	Spiractin tablets 25 mg	0	0.0	0.0	0.0	0.0	6.1
	Aldactone tablets 25 mg	0	0.0	0.0	0.0	0.0	6.6
	Aldactone tablets 100 mg	5	0.0	0.0	0.5	0.4	81.1
Bisoprolol fumarate	Aldactone tablets 100 mg	0	0.0	0.0	0.0	0.0	6.1
	Bicor NOS	6	0.0	0.0	0.6	0.5	.
	Bicor tablets 5 mg	1	0.0	0.0	0.1	0.0	9.8
	Bicor tablets 10 mg	3	0.0	0.0	0.3	0.2	50.7
Candesartan cilexetil	Bicor tablets 10 mg	2	0.0	0.0	0.2	0.2	39.5
	Candesartan cilexetil	6	0.0	0.0	0.6	0.5	.

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
	Atacand tablets 8 mg	4	0.0	0.0	0.4	0.3	74.3
	Atacand tablets 16 mg	1	0.0	0.0	0.1	0.1	25.7
Dipyridamole/Aspirin		6	0.0	0.0	0.6	0.5	.
	Asasantin capsules 225 mg	6	0.0	0.0	0.6	0.5	100.0
Atorvastatin/Amlodipine		5	0.0	0.0	0.5	0.4	.
	Caduet tablets 45 mg	3	0.0	0.0	0.3	0.3	64.1
	Caduet tablets 50 mg	2	0.0	0.0	0.2	0.1	35.9
Lercanidipine		5	0.0	0.0	0.5	0.4	.
	Lercanidipine tablets 20 mg	1	0.0	0.0	0.1	0.1	19.0
	Zanidip tablets 10 mg	3	0.0	0.0	0.3	0.2	53.9
	Zanidip tablets 20 mg	1	0.0	0.0	0.1	0.1	27.1
Amiodarone hcl		5	0.0	0.0	0.5	0.4	.
	Amiodarone hcl tablets 100 mg	0	0.0	0.0	0.0	0.0	8.8
	Amiodarone hcl tablets 200 mg	3	0.0	0.0	0.3	0.3	71.2
	Aratac tablets 100 mg	1	0.0	0.0	0.1	0.1	19.9
Enalapril mal		4	0.0	0.0	0.4	0.4	.
	Renitec tablets 20 mg	4	0.0	0.0	0.4	0.4	100.0
Isosorbide dinitrate		4	0.0	0.0	0.4	0.4	.
	Isosorbide dinitrate Tablets 10 mg	1	0.0	0.0	0.1	0.1	29.8
	Sorbidin tablets 10 mg	1	0.0	0.0	0.1	0.1	16.0
	Isordil tablets 10 mg	1	0.0	0.0	0.1	0.1	17.5
	Isordil tablets sublingual 5 mg	2	0.0	0.0	0.2	0.1	36.7
Nifedipine		4	0.0	0.0	0.4	0.3	.
	Adefin XL tablets 30 mg	1	0.0	0.0	0.1	0.1	25.1
	Adalat oros tablets 30 mg	3	0.0	0.0	0.3	0.2	66.2
	Adalat oros tablets 20 mg	0	0.0	0.0	0.0	0.0	8.7
Influenza virus vaccine		3	0.0	0.0	0.3	0.3	.
	Influenza virus vaccine 0.5 ml	1	0.0	0.0	0.1	0.1	28.8
	Fluvax injection 0.5 ml	2	0.0	0.0	0.2	0.2	71.2
Omeprazole		3	0.0	0.0	0.3	0.2	.
	Omeprazole NOS	1	0.0	0.0	0.1	0.1	21.5
	Losec tablets 20 mg	2	0.0	0.0	0.2	0.2	78.5
Irbesartan/Hydrochlorothiazide		3	0.0	0.0	0.3	0.2	.

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
	Avapro HCT tablets 162.5 mg	0	0.0	0.0	0.0	0.0	13.1
	Avapro HCT tablets 312.5 mg	1	0.0	0.0	0.1	0.1	22.8
	Karvezide tablets 162.5 mg	1	0.0	0.0	0.1	0.1	37.7
	Karvezide tablets 312.5 mg	1	0.0	0.0	0.1	0.1	26.3
Fenofibrate		3	0.0	0.0	0.2	0.2	.
	Fenofibrate NOS	2	0.0	0.0	0.1	0.1	59.5
	Lipidil tablets 145 mg	1	0.0	0.0	0.1	0.1	40.5
Indapamide		3	0.0	0.0	0.2	0.2	.
	Indapamide tablets 1.5 mg	1	0.0	0.0	0.1	0.1	40.8
	Natrilix tablets SR 1.5 mg	1	0.0	0.0	0.1	0.1	59.2
Potassium chloride		2	0.0	0.0	0.2	0.2	.
	Slow-K tablets 600 mg	2	0.0	0.0	0.2	0.2	100.0
Simvastatin/Ezetimibe		2	0.0	0.0	0.2	0.2	.
	Vytorin tablets 50 mg	2	0.0	0.0	0.2	0.2	81.0
	Vytorin tablets 90 mg	0	0.0	0.0	0.0	0.0	19.0
Thyroxine		2	0.0	0.0	0.2	0.2	.
	Oroxine tablets 100 mcg	2	0.0	0.0	0.2	0.2	100.0
Diltiazem anti-angina		2	0.0	0.0	0.2	0.2	.
	Diltiazem anti-angina Tablets 60 mg	2	0.0	0.0	0.2	0.2	100.0
Perindopril/Indapamide		2	0.0	0.0	0.2	0.2	.
	Coversyl Plus tablets 5.25 mg	2	0.0	0.0	0.2	0.2	100.0
Propranolol hydrochloride		2	0.0	0.0	0.2	0.2	.
	Inderal NOS	1	0.0	0.0	0.1	0.1	29.5
	Inderal tablets 40 mg	2	0.0	0.0	0.1	0.1	70.5
Felodipine		2	0.0	0.0	0.2	0.2	.
	Felodur tablets 2.5 mg	1	0.0	0.0	0.1	0.1	48.5
	Felodur tablets 10 mg	1	0.0	0.0	0.1	0.1	51.5
Metformin		2	0.0	0.0	0.2	0.2	.
	Metformin Tablets 500 mg	1	0.0	0.0	0.1	0.1	40.5
	Metformin tablets 1 g	1	0.0	0.0	0.1	0.1	40.5
	Diabex tablets 500 mg	0	0.0	0.0	0.0	0.0	19.0
Trianterene/Hydrochlorothiazide		2	0.0	0.0	0.2	0.1	.
	Hydrene tablets 75 mg	2	0.0	0.0	0.2	0.1	100.0

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Flecainide acetate		2	0.0	0.0	0.2	0.1	.
	Flecainide acetate Tablets 100 mg	1	0.0	0.0	0.1	0.1	60.3
	Tambocor tablets 50 mg	1	0.0	0.0	0.1	0.1	39.7
Illegible		2	0.0	0.0	0.2	0.1	.
	Illegible	2	0.0	0.0	0.2	0.1	100.0
Telmisartan/Hydrochlorothiazide		2	0.0	0.0	0.2	0.1	.
	Micardis plus 80/12.5 tablets 92.5 mg	2	0.0	0.0	0.2	0.1	100.0
Prednisolone		2	0.0	0.0	0.2	0.1	.
	Prednisolone NOS	2	0.0	0.0	0.2	0.1	100.0
Fosinopril		2	0.0	0.0	0.2	0.1	.
	Monopril tablets 10 mg	1	0.0	0.0	0.1	0.1	61.2
	Monopril tablets 20 mg	1	0.0	0.0	0.1	0.0	38.8
Candesartan/Hydrochlorothiazide		2	0.0	0.0	0.1	0.1	.
	Atacand plus tablets 28.5 mg	2	0.0	0.0	0.1	0.1	100.0
Tiotropium		1	0.0	0.0	0.1	0.1	.
	Spiriva powder resp 18 mcg	1	0.0	0.0	0.1	0.1	100.0
Allopurinol		1	0.0	0.0	0.1	0.1	.
	Allopurinol NOS	1	0.0	0.0	0.1	0.1	100.0
Betamethasone topical		1	0.0	0.0	0.1	0.1	.
	Celestone M cream/ointment 0.2 mg 1 g	1	0.0	0.0	0.1	0.1	100.0
Diazepam		1	0.0	0.0	0.1	0.1	.
	Antenex tablets 5 mg	0	0.0	0.0	0.0	0.0	25.4
	Valium NOS	1	0.0	0.0	0.1	0.1	74.6
Risedronate sodium		1	0.0	0.0	0.1	0.1	.
	Actonel NOS	1	0.0	0.0	0.1	0.1	100.0
Herbal remedy nec		1	0.0	0.0	0.1	0.1	.
	Herbal remedy nec	1	0.0	0.0	0.1	0.1	100.0
Vitamin D3 (Cholecalciferol)		1	0.0	0.0	0.1	0.1	.
	Ostelin capsules 25 mcg	1	0.0	0.0	0.1	0.1	100.0
Oxygen		1	0.0	0.0	0.1	0.1	.
	Oxygen	1	0.0	0.0	0.1	0.1	100.0
Dipyridamole		1	0.0	0.0	0.1	0.1	.
	Persantin NOS	1	0.0	0.0	0.1	0.1	100.0

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Lumiracoxib		1	0.0	0.0	0.1	0.1	.
	Prexige NOS	1	0.0	0.0	0.1	0.1	100.0
Fosinopril/Hydrochlorothiazide		1	0.0	0.0	0.1	0.1	.
	Monoplus 10/12.5 tablets 22.5 mg	1	0.0	0.0	0.1	0.1	100.0
Fluvastatin		1	0.0	0.0	0.1	0.1	.
	Lescol xl capsules 80 mg	1	0.0	0.0	0.1	0.1	100.0
Temazepam		1	0.0	0.0	0.1	0.1	.
	Temaze NOS	1	0.0	0.0	0.1	0.1	100.0
Sumatriptan		1	0.0	0.0	0.1	0.1	.
	Imigran NOS	1	0.0	0.0	0.1	0.1	100.0
Amitriptyline		1	0.0	0.0	0.1	0.1	.
	Endep tablets 25 mg	1	0.0	0.0	0.1	0.1	100.0
Nitrazepam		1	0.0	0.0	0.1	0.1	.
	Nitrazepam Tablets 5 mg	1	0.0	0.0	0.1	0.1	100.0
Gemfibrozil		1	0.0	0.0	0.1	0.1	.
	Jezil tablets 600 mg	1	0.0	0.0	0.1	0.1	100.0
Telmisartan		1	0.0	0.0	0.1	0.1	.
	Micardis tablets 40 mg	1	0.0	0.0	0.1	0.1	100.0
Captopril		1	0.0	0.0	0.1	0.1	.
	Acenorm tablets 25 mg	1	0.0	0.0	0.1	0.1	100.0
Quinapril		1	0.0	0.0	0.1	0.1	.
	Accupril tablets 10 mg	1	0.0	0.0	0.1	0.1	100.0
Folic acid		1	0.0	0.0	0.1	0.0	.
	Megafol tablets 500 mcg	1	0.0	0.0	0.1	0.0	100.0
Enoxaparin		1	0.0	0.0	0.1	0.0	.
	Clexane NOS	1	0.0	0.0	0.1	0.0	100.0
Paracetamol		0	0.0	0.0	0.0	0.0	.
	Paracetamol Tablets 500 mg	0	0.0	0.0	0.0	0.0	100.0
Pneumococcal vaccine		0	0.0	0.0	0.0	0.0	.
	Pneumovax 23 injection 0.5 ml	0	0.0	0.0	0.0	0.0	100.0
Vitamin B3 (Nicotinamide oral)		0	0.0	0.0	0.0	0.0	.
	Vitamin B3 (Nicotinamide oral)	0	0.0	0.0	0.0	0.0	100.0
Clozapine		0	0.0	0.0	0.0	0.0	.

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.3: All medications (generic and products within each generic)* - IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	per 100 total probs	per 100 IHD 45+ probs	% of IHD 45+ meds	% of generic
Lansoprazole	Clopine tablets 100 mg	0	0.0	0.0	0.0	0.0	100.0
	Zoton NOS	0	0.0	0.0	0.0	0.0	.
Meloxicam		0	0.0	0.0	0.0	0.0	.
Alprazolam	Movalis tablets 15 mg	0	0.0	0.0	0.0	0.0	100.0
	Xanax tablets 2 mg	0	0.0	0.0	0.0	0.0	.

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.4: Prescribed daily dose* - IHD 45+ Apr07-Mar08 wgt

Generic label	n	Mean PDD	Measure	Lower 95% CI	Upper 95% CI	Median PDD	Minimum	Maximum
Clopidogrel	128	74.9	mg	74.8	75.1	75.000	70.000	75.00
Aspirin cardiovascular	102	100.0	mg	100.0	100.0	100.000	100.000	100.00
Atorvastatin	92	39.0	mg	34.0	43.9	40.000	10.000	80.00
Isosorbide mononitrate	77	79.3	mg	70.1	88.5	60.000	30.000	120.00
Metoprolol	62	81.5	mg	67.3	95.7	50.000	25.000	200.00
Simvastatin	54	41.2	mg	34.0	48.4	40.000	10.000	80.00
Ramipril	50	5.4	mg	4.3	6.4	5.000	1.250	10.00
Atenolol	42	39.8	mg	32.2	47.3	50.000	2.500	150.00
Perindopril	29	4.8	mg	3.8	5.8	5.000	2.500	10.00
Diltiazem anti-hypertensive	27	236.0	mg	207.2	264.8	240.000	180.000	360.00
Nicorandil	26	25.8	mg	19.4	32.1	20.000	5.000	40.00
Irbesartan	16	200.1	mg	136.4	263.8	150.000	75.000	300.00
Frusemide (Furosemide)	16	48.1	mg	32.1	64.2	40.000	20.000	120.00
Rosuvastatin	14	10.5	mg	8.7	12.3	10.000	5.000	20.00
Aspirin	13	160.7	mg	131.4	190.1	150.000	100.000	300.00
Carvedilol	13	23.4	mg	16.5	30.3	25.000	12.500	50.00
Pravastatin	11	39.0	mg	26.5	51.5	40.000	20.000	80.00
Ezetimibe	11	9.4	mg	8.3	10.6	10.000	5.000	10.00
Digoxin	11	0.2	mg	0.1	0.2	0.125	0.063	0.25
Warfarin sodium	9	3.8	mg	2.5	5.0	5.000	1.000	5.00
Lisinopril	7	16.4	mg	3.1	29.8	20.000	5.000	40.00
Amlodipine	7	7.3	mg	5.1	9.5	5.000	5.000	10.00
Perhexiline	7	112.6	mg	80.6	144.6	100.000	100.000	200.00
GTN (glyceryl trinitrate)	7	13.2	mg	4.5	22.0	5.000	5.000	25.00
Spironolactone	6	29.0	mg	0.0	58.2	25.000	12.500	100.00
Bisoprolol fumarate	6	6.9	mg	2.5	11.2	5.000	4.000	10.00
Candesartan cilexetil	6	10.1	mg	5.5	14.6	8.000	8.000	16.00
Sotalol	5	106.7	mg	20.4	192.9	80.000	40.000	160.00
Dipyridamole/Aspirin	5	450.0	mg	450.0	450.0	450.000	450.000	450.00
Atorvastatin/Amlodipine	5	46.8	mg	43.4	50.2	45.000	45.000	50.00
Lercanidipine	5	11.7	mg	7.2	16.3	10.000	10.000	20.00
Verapamil hydrochloride	5	260.5	mg	94.3	426.7	240.00	80.00	480.00
Enalapril mal	4	20.0	mg	20.0	20.0	20.00	20.00	20.00
Amiodarone hcl	4	158.4	mg	86.4	230.4	200.00	100.00	200.00
Omeprazole	3	20.0	mg	.	.	20.00	20.00	20.00
Irbesartan/Hydrochlorothiazide	3	318.6	mg	.	.	162.50	162.50	625.00

* This table includes medications prescribed by GPs.

The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 7.4: Prescribed daily dose* - IHD 45+ Apr07-Mar08 wgttd

Generic label	n	Mean PDD	Measure	Lower 95% CI	Upper 95% CI	Median PDD	Minimum	Maximum
Isosorbide dinitrate	3	30.6	mg	.	.	30.00	15.00	40.00
Fenofibrate	3	87.3	mg	.	.	48.00	48.00	145.00
Indapamide	3	1.5	mg	.	.	1.50	1.50	1.50
Potassium chloride	2	2098.0	mg	.	.	3000.00	600.00	3600.00
Thyroxine	2	0.1	mg	.	.	0.10	0.10	0.10
Perindopril/Indapamide	2	5.3	mg	.	.	5.25	5.25	5.25
Propranolol hydrochloride	2	142.3	mg	.	.	160.00	100.00	160.00
Felodipine	2	6.4	mg	.	.	10.00	2.50	10.00
Nifedipine	2	28.4	mg	.	.	30.00	20.00	30.00
Metformin	2	702.4	mg	.	.	500.00	500.00	1000.00
Simvastatin/Ezetimibe	2	60.0	mg	.	.	50.00	50.00	90.00
Flecainide acetate	2	100.0	mg	.	.	100.00	100.00	100.00
Telmisartan/Hydrochlorothiazide	2	92.5	mg	.	.	92.50	92.50	92.50
Prednisolone	2	40.0	mg	.	.	40.00	40.00	40.00
Fosinopril	2	13.9	mg	.	.	10.00	10.00	20.00
Candesartan/Hydrochlorothiazide	2	28.5	mg	.	.	28.50	28.50	28.50
Allopurinol	1	100.0	mg	.	.	100.00	100.00	100.00
Diazepam	1	8.7	mg	.	.	10.00	5.00	10.00
Risedronate sodium	1	20.0	mg	.	.	20.00	20.00	20.00
Lumiracoxib	1	250.0	mg	.	.	250.00	250.00	250.00
Fosinopril/Hydrochlorothiazide	1	22.5	mg	.	.	22.50	22.50	22.50
Fluvastatin	1	80.0	mg	.	.	80.00	80.00	80.00
Amitriptyline	1	50.0	mg	.	.	50.00	50.00	50.00
Nitrazepam	1	5.0	mg	.	.	5.00	5.00	5.00
Gemfibrozil	1	1200.0	mg	.	.	1200.00	1200.00	1200.00
Captopril	1	25.0	mg	.	.	25.00	25.00	25.00
Tiotropium	1	0.0	mg	.	.	0.02	0.02	0.02
Paracetamol	0	4000.0	mg	.	.	4000.00	4000.00	4000.00
Telmisartan	0	40.0	mg	.	.	40.00	40.00	40.00
Lansoprazole	0	30.0	mg	.	.	30.00	30.00	30.00
Meloxicam	0	15.0	mg	.	.	15.00	15.00	15.00
Alprazolam	0	2.0	mg	.	.	2.00	2.00	2.00

* This table includes medications prescribed by GPs.

The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 8.1: Frequency of medication provision - New IHD 45+ Apr07-Mar08 wgted

Data	n	Per 100 new IHD 45+	Lower 95% CI	Upper 95% CI	% of meds for new IHD 45+ probs	Lower 95% CI	Upper 95% CI
Medications	83	96.5	67.9	125.0	100.0	100.0	100.0

- Prescribed	73	85.4	56.5	114.2	88.5	79.9	97.1
- Advised OTC	6	7.1	1.5	12.7	7.4	1.1	13.6
- GP supplied	3	4.0	0.0	9.4	4.2	0.0	9.8

Table 8.2: Top 30 medications prescribed - ATC (WHO) Level 2 (3 digits) - New IHD 45+ Apr07-Mar08 wgttd

ATC label	ATC 3 digit code	n	Per 100 new IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for new IHD 45+	Lower 95% CI	Upper 95% CI
CARDIAC THERAPY	C01	24	28.2	17.1	39.3	33.0	20.2	45.9
ANTITHROMBOTIC AGENTS	B01	15	17.7	7.7	27.8	20.8	12.9	28.7
BETA BLOCKING AGENTS	C07	12	13.4	5.2	21.7	15.8	8.1	23.4
LIPID MODIFYING AGENTS	C10	10	12.0	4.2	19.7	14.0	6.5	21.5
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	C09	10	11.5	3.5	19.4	13.4	6.1	20.8
CALCIUM CHANNEL BLOCKERS	C08	1	1.4	.	.	1.6	.	.
ANALGESICS	N02	1	0.6	.	.	0.7	.	.
DIURETICS	C03	0	0.6	.	.	0.7	.	.
Subtotal		73	.	.	.	100.0	.	.
Other Meds		0	.	.	.	0.0	.	.
Total Meds		73	85.4	56.5	114.2	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 3 digit ATC level, but could be coded at 1 digit ATC code. Also some medications were mapped to 1 digit ATC codes, because there was not an appropriate 3 digit ATC code available at the time.

Table 8.2.1: Top 30 medications prescribed - ATC (WHO) Level 3 (4 digits) - New IHD 45+ Apr07-Mar08 wgt'd

ATC label	ATC 4 digit code	n	Per 100 new IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for new IHD 45+	Lower 95% CI	Upper 95% CI
VASODILATORS USED IN CARDIAC DISEASES	C01D	23	26.6	15.7	37.5	31.2	17.7	44.6
ANTITHROMBOTIC AGENTS	B01A	15	17.7	7.7	27.8	20.8	12.9	28.7
BETA BLOCKING AGENTS	C07A	12	13.4	5.2	21.7	15.8	8.1	23.4
LIPID MODIFYING AGENTS, PLAIN	C10A	10	12.0	4.2	19.7	14.0	6.5	21.5
ACE INHIBITORS, PLAIN	C09A	8	9.0	1.9	16.0	10.5	3.6	17.3
ANTIARRHYTHMICS, CLASS I AND III	C01B	1	1.6	.	.	1.9	.	.
ANGIOTENSIN II ANTAGONISTS, PLAIN	C09C	1	1.6	.	.	1.8	.	.
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	C08C	1	1.4	.	.	1.6	.	.
ACE INHIBITORS, COMBINATIONS	C09B	1	1.0	.	.	1.1	.	.
OTHER ANALGESICS AND ANTIPYRETICS	N02B	1	0.6	.	.	0.7	.	.
HIGH-CEILING DIURETICS	C03C	0	0.6	.	.	0.7	.	.
	
Subtotal		73	.	.	.	100.0	.	.
	
Other Meds		0	.	.	.	0.0	.	.
	
Total Meds		73	85.4	56.5	114.2	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 4 digit ATC level, but could be coded at 1, or 3 digit ATC level. Also some medications were mapped to 1 or 3 digit ATC codes, because there was not an appropriate 4 digit ATC code available at the time.

Table 8.2.2: Top 30 medications prescribed - ATC (WHO) Level 4 (5 digits) - New IHD 45+ Apr07-Mar08 wgt'd

ATC label	ATC 5 digit code	n	Per 100 new IHD 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for new IHD 45+	Lower 95% CI	Upper 95% CI
Organic nitrates	C01DA	23	26.6	15.7	37.5	31.2	17.7	44.6
Platelet aggregation inhibitors excl. heparin	B01AC	15	17.7	7.7	27.8	20.8	12.9	28.7
Beta blocking agents, selective	C07AB	12	13.4	5.2	21.7	15.8	8.1	23.4
HMG CoA reductase inhibitors	C10AA	10	11.5	3.8	19.3	13.5	6.1	20.9
ACE inhibitors, plain	C09AA	8	9.0	1.9	16.0	10.5	3.6	17.3
Antiarrhythmics, class III	C01BD	1	1.6	.	.	1.9	.	.
Angiotensin II antagonists, plain	C09CA	1	1.6	.	.	1.8	.	.
Dihydropyridine derivatives	C08CA	1	1.4	.	.	1.6	.	.
ACE inhibitors and diuretics	C09BA	1	1.0	.	.	1.1	.	.
Salicylic acid and derivatives	N02BA	1	0.6	.	.	0.7	.	.
Sulfonamides, plain	C03CA	0	0.6	.	.	0.7	.	.
Other lipid modifying agents	C10AX	0	0.4	.	.	0.5	.	.
	
Subtotal		73	.	.	.	100.0	.	.
	
Other Meds		0	.	.	.	0.0	.	.
	
Total Meds		73	85.4	56.5	114.2	100.0	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 5 digit ATC level, but could be coded at 1, 3 or 4 digit ATC level. Also some medications were mapped to 1, 3 or 4 digit ATC codes, because there was not an appropriate 5 digit ATC code available at the time.

Table 8.2.3: Top 60 generic medications prescribed - CAPS generic (4 digits) - New IHD 45+ Apr07-Mar08 wgt'd

CAPS generic	CAPS 4 digit code	n	Per 100 new IHD 45+ probs	Lower		Upper		% of prescribed meds for new IHD 45+	Lower		Upper	
				95% CI	95% CI	95% CI	95% CI		95% CI	95% CI		
GTN (glyceryl trinitrate)	C301	18	21.3	10.7	32.0	25.0	13.1	36.9				
Metoprolol	C505	10	12.1	4.3	19.8	14.1	6.6	21.7				
Aspirin cardiovascular	B238	10	11.3	3.6	18.9	13.2	6.9	19.4				
Clopidogrel	B218	6	6.5	0.6	12.4	7.6	0.9	14.3				
Rosuvastatin	C965	4	5.2	0.1	10.4	6.1	0.6	11.7				
Perindopril	C117	3	4.0	0.0	8.7	4.7	0.0	9.8				
Ramipril	C122	3	3.6	0.0	8.5	4.2	0.0	9.8				
Atorvastatin	C959	3	3.4	.	.	4.0	.	.				
Isosorbide mononitrate	C307	3	3.3	.	.	3.9	.	.				
Isosorbide dinitrate	C302	2	2.0	.	.	2.3	.	.				
Simvastatin	C954	1	1.7	.	.	2.0	.	.				
Amiodarone hcl	C207	1	1.6	.	.	1.9	.	.				
Atenolol	C504	1	1.4	.	.	1.6	.	.				
Lisinopril	C119	1	1.4	.	.	1.6	.	.				
Amlodipine	C123	1	1.4	.	.	1.6	.	.				
Fluvastatin	C957	1	1.2	.	.	1.4	.	.				
Candesartan cilexetil	C130	1	1.1	.	.	1.3	.	.				
Perindopril/Indapamide	C135	1	1.0	.	.	1.1	.	.				
Aspirin	N107	1	0.6	.	.	0.7	.	.				
Furosemide (Furosemide)	U204	0	0.6	.	.	0.7	.	.				
Ezetimibe	C962	0	0.4	.	.	0.5	.	.				
Irbesartan	C128	0	0.4	.	.	0.5	.	.				
Subtotal		73	.	.	.	100.0	.	.				
Other Meds		0	.	.	.	0.0	.	.				
Total Meds		73	85.4	56.5	114.2	100.0	.	.				

Table 8.2.4: Prescribed medications (generic and products within each generic)
- New IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total prescribed meds	Per 100 total probs	% of prescribed meds for new IHD 45+ probs	% of generic
Total prescribed IHD 45+ medication		73	0.1	0.1	.	.
GTN (glyceryl trinitrate)		18	0.0	0.0	25.0	.
	GTN (glyceryl trinitrate) NOS	2	0.0	0.0	3.3	13.2
	GTN (glyceryl trinitrate) Sublingual 400 mcg	2	0.0	0.0	3.2	12.7
	Anginine tablets 600 mcg	3	0.0	0.0	3.7	15.0
	Nitrolingual spray sublingual 400 mcg	9	0.0	0.0	12.0	48.0
	Nitro-dur patches 5 mg	2	0.0	0.0	2.8	11.2
Metoprolol		10	0.0	0.0	14.1	.
	Metoprolol NOS	2	0.0	0.0	2.1	14.9
	Metoprolol Tablets 50 mg	3	0.0	0.0	4.0	28.4
	Metoprolol Tablets 100 mg	1	0.0	0.0	1.2	8.1
	Minax tablets 50 mg	1	0.0	0.0	1.6	11.4
	Betaloc tablets 50 mg	4	0.0	0.0	5.3	37.1
Aspirin cardiovascular		10	0.0	0.0	13.2	.
	Aspirin tablets 100 mg	1	0.0	0.0	1.8	13.9
	Astrix NOS	6	0.0	0.0	7.5	57.0
	Cartia tablets 100 mg	3	0.0	0.0	3.8	29.1
Clopidogrel		6	0.0	0.0	7.6	.
	Iscover tablets 75 mg	1	0.0	0.0	1.7	22.4
	Plavix tablets 75 mg	4	0.0	0.0	5.9	77.6
Rosuvastatin		4	0.0	0.0	6.1	.
	Crestor tablets 10 mg	4	0.0	0.0	5.4	88.6
	Crestor tablets 20 mg	1	0.0	0.0	0.7	11.4
Perindopril		3	0.0	0.0	4.7	.
	Perindopril tablets 2.5 mg	1	0.0	0.0	1.1	23.9
	Coversyl tablets 2.5 mg	1	0.0	0.0	1.6	34.1
	Coversyl tablets 5 mg	1	0.0	0.0	2.0	41.9
Ramipril		3	0.0	0.0	4.2	.
	Ramipril Tablets 2.5 mg	1	0.0	0.0	1.1	27.5
	Tritace tablets 2.5 mg	1	0.0	0.0	1.9	45.1
	Tritace tablets 5 mg	1	0.0	0.0	1.1	27.5

Table 8.2.4: Prescribed medications (generic and products within each generic)
- New IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total prescribed meds	Per 100 total probs	% of prescribed meds for new IHD 45+ probs	% of generic
Atorvastatin		3	0.0	0.0	4.0	.
	Lipitor tablets 40 mg	2	0.0	0.0	2.1	52.9
	Lipitor tablets 80 mg	1	0.0	0.0	1.9	47.1
Isosorbide mononitrate		3	0.0	0.0	3.9	.
	Imdur tablets 60 mg	3	0.0	0.0	3.9	100.0
Isosorbide dinitrate		2	0.0	0.0	2.3	.
	Isosorbide dinitrate Tablets 10 mg	1	0.0	0.0	1.7	74.8
	Isordil tablets sublingual 5 mg	0	0.0	0.0	0.6	25.2
Simvastatin		1	0.0	0.0	2.0	.
	Simvastatin Tablets 40 mg	1	0.0	0.0	2.0	100.0
Amiodarone hcl		1	0.0	0.0	1.9	.
	Amiodarone hcl tablets 200 mg	1	0.0	0.0	1.9	100.0
Atenolol		1	0.0	0.0	1.6	.
	Noten tablets 50 mg	1	0.0	0.0	1.6	100.0
Lisinopril		1	0.0	0.0	1.6	.
	Zestril tablets 20 mg	1	0.0	0.0	1.6	100.0
Amlodipine		1	0.0	0.0	1.6	.
	Norvasc tablets 10 mg	1	0.0	0.0	1.6	100.0
Fluvastatin		1	0.0	0.0	1.4	.
	Lescol xl capsules 80 mg	1	0.0	0.0	1.4	100.0
Candesartan cilexetil		1	0.0	0.0	1.3	.
	Atacand tablets 8 mg	1	0.0	0.0	1.3	100.0
Perindopril/Indapamide		1	0.0	0.0	1.1	.
	Coversyl Plus tablets 5.25 mg	1	0.0	0.0	1.1	100.0
Aspirin		1	0.0	0.0	0.7	.
	Aspirin NOS	1	0.0	0.0	0.7	100.0
Frusemide (Furosemide)		0	0.0	0.0	0.7	.
	Lasix tablets 20 mg	0	0.0	0.0	0.7	100.0
Ezetimibe		0	0.0	0.0	0.5	.
	Ezetrol tablets 10 mg	0	0.0	0.0	0.5	100.0
Irbesartan		0	0.0	0.0	0.5	.
	Avapro tablets 150 mg	0	0.0	0.0	0.5	100.0

Table 8.2.5.1: Top 60 medications prescribed (grouped by brand) in alphabetic order
-New IHD 45+ Apr07-Mar08 wgt

brand	n	% of prescribed meds for new IHD 45+	per 100 new IHD 45+	% of total prescribed meds	per 100 total problems
Amiodarone hcl	1	1.9	1.6	0.0	0.0
Anginine	3	3.7	3.2	0.0	0.0
Aspirin	2	2.5	2.2	0.0	0.0
Astrix	6	7.5	6.4	0.0	0.0
Atacand	1	1.3	1.1	0.0	0.0
Avapro	0	0.5	0.4	0.0	0.0
Betaloc	4	5.3	4.5	0.0	0.0
Cartia	3	3.8	3.3	0.0	0.0
Coversyl	3	3.6	3.1	0.0	0.0
Coversyl Plus	1	1.1	1.0	0.0	0.0
Crestor	4	6.1	5.2	0.0	0.0
Ezetrol	0	0.5	0.4	0.0	0.0
GTN (glyceryl trinitrate)	5	6.5	5.5	0.0	0.0
Imdur	3	3.9	3.3	0.0	0.0
Iscover	1	1.7	1.5	0.0	0.0
Isordil	0	0.6	0.5	0.0	0.0
Isosorbide dinitrate	1	1.7	1.5	0.0	0.0
Lasix	0	0.7	0.6	0.0	0.0
Lescol	1	1.4	1.2	0.0	0.0
Lipitor	3	4.0	3.4	0.0	0.0
Metoprolol	5	7.3	6.2	0.0	0.0
Minax	1	1.6	1.4	0.0	0.0
Nitro-dur	2	2.8	2.4	0.0	0.0
Nitrolingual	9	12.0	10.2	0.0	0.0
Norvasc	1	1.6	1.4	0.0	0.0
Noten	1	1.6	1.4	0.0	0.0
Perindopril	1	1.1	1.0	0.0	0.0
Plavix	4	5.9	5.0	0.0	0.0
Ramipril	1	1.1	1.0	0.0	0.0
Simvastatin	1	2.0	1.7	0.0	0.0
Tritace	2	3.0	2.6	0.0	0.0
Zestril	1	1.6	1.4	0.0	0.0
.
Subtotal	73	100.0	85.4	0.1	0.1
.
Total Meds	73	100.0	85.4	0.1	0.1

Table 8.2.5.2: Top 60 medications prescribed (grouped by brand) in frequency descending order
-New IHD 45+ Apr07-Mar08 wgt

brand	n	% of prescribed meds for new IHD 45+ probs	per 100 new IHD 45+ probs	% of total prescribed meds	per 100 total probs
Nitrolingual	9	12.0	10.2	0.0	0.0
Astrix	6	7.5	6.4	0.0	0.0
Metoprolol	5	7.3	6.2	0.0	0.0
GTN (glyceryl trinitrate)	5	6.5	5.5	0.0	0.0
Crestor	4	6.1	5.2	0.0	0.0
Plavix	4	5.9	5.0	0.0	0.0
Betaloc	4	5.3	4.5	0.0	0.0
Lipitor	3	4.0	3.4	0.0	0.0
Imdur	3	3.9	3.3	0.0	0.0
Cartia	3	3.8	3.3	0.0	0.0
Anginine	3	3.7	3.2	0.0	0.0
Coversyl	3	3.6	3.1	0.0	0.0
Tritace	2	3.0	2.6	0.0	0.0
Nitro-dur	2	2.8	2.4	0.0	0.0
Aspirin	2	2.5	2.2	0.0	0.0
Simvastatin	1	2.0	1.7	0.0	0.0
Amiodarone hcl	1	1.9	1.6	0.0	0.0
Isosorbide dinitrate	1	1.7	1.5	0.0	0.0
Iscover	1	1.7	1.5	0.0	0.0
Minax	1	1.6	1.4	0.0	0.0
Noten	1	1.6	1.4	0.0	0.0
Norvasc	1	1.6	1.4	0.0	0.0
Zestril	1	1.6	1.4	0.0	0.0
Lescol	1	1.4	1.2	0.0	0.0
Atacand	1	1.3	1.1	0.0	0.0
Ramipril	1	1.1	1.0	0.0	0.0
Coversyl Plus	1	1.1	1.0	0.0	0.0
Perindopril	1	1.1	1.0	0.0	0.0
Lasix	0	0.7	0.6	0.0	0.0
Isordil	0	0.6	0.5	0.0	0.0
Ezetrol	0	0.5	0.4	0.0	0.0
Avapro	0	0.5	0.4	0.0	0.0
.
Subtotal	73	100.0	85.4	0.1	0.1
.
Total Meds	73	100.0	85.4	0.1	0.1

Table 8.3: All medications (generic and products within each generic)*
- New IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	Per 100 total probs	% of meds for new IHD 45+	% of generic
Total IHD 45+ medications		83	0.1	0.1	.	.
GTN (glyceryl trinitrate)		20	0.0	0.0	24.1	.
	GTN (glyceryl trinitrate) NOS	2	0.0	0.0	2.9	12.1
	GTN (glyceryl trinitrate) Sublingual 400 mcg	3	0.0	0.0	3.4	14.3
	Anginine tablets 600 mcg	3	0.0	0.0	4.2	17.4
	Nitrolingual spray sublingual 400 mcg	9	0.0	0.0	11.1	46.0
	Nitro-dur patches 5 mg	2	0.0	0.0	2.5	10.2
Aspirin cardiovascular		12	0.0	0.0	14.1	.
	Aspirin tablets 100 mg	1	0.0	0.0	1.6	11.5
	Astrix NOS	6	0.0	0.0	6.6	47.2
	Astrix tablets 100 mg	1	0.0	0.0	1.2	8.3
	Cartia tablets 100 mg	4	0.0	0.0	4.7	33.1
Metoprolol		10	0.0	0.0	12.5	.
	Metoprolol NOS	2	0.0	0.0	1.9	14.9
	Metoprolol Tablets 50 mg	3	0.0	0.0	3.6	28.4
	Metoprolol Tablets 100 mg	1	0.0	0.0	1.0	8.1
	Minax tablets 50 mg	1	0.0	0.0	1.4	11.4
	Betaloc tablets 50 mg	4	0.0	0.0	4.6	37.1
Clopidogrel		6	0.0	0.0	6.7	.
	Iscover tablets 75 mg	1	0.0	0.0	1.5	22.4
	Plavix tablets 75 mg	4	0.0	0.0	5.2	77.6
Rosuvastatin		4	0.0	0.0	5.4	.
	Crestor tablets 10 mg	4	0.0	0.0	4.8	88.6
	Crestor tablets 20 mg	1	0.0	0.0	0.6	11.4
Aspirin		4	0.0	0.0	4.9	.
	Aspirin NOS	2	0.0	0.0	2.2	44.0
	Aspirin tablets 300 mg	2	0.0	0.0	2.8	56.0
Perindopril		3	0.0	0.0	4.2	.
	Perindopril tablets 2.5 mg	1	0.0	0.0	1.0	23.9
	Coversyl tablets 2.5 mg	1	0.0	0.0	1.4	34.1
	Coversyl tablets 5 mg	1	0.0	0.0	1.8	41.9
Ramipril		3	0.0	0.0	3.7	.
	Ramipril Tablets 2.5 mg	1	0.0	0.0	1.0	27.5
	Tritace tablets 2.5 mg	1	0.0	0.0	1.7	45.1
	Tritace tablets 5 mg	1	0.0	0.0	1.0	27.5

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 8.3: All medications (generic and products within each generic)*
- New IHD 45+ Apr07-Mar08 wgttd

Generic	Product	n	% of total meds	Per 100 total probs	% of meds for new IHD 45+	% of generic
Atorvastatin		3	0.0	0.0	3.5	.
	Lipitor tablets 40 mg	2	0.0	0.0	1.9	52.9
	Lipitor tablets 80 mg	1	0.0	0.0	1.7	47.1
Isosorbide mononitrate		3	0.0	0.0	3.4	.
	Imdur tablets 60 mg	3	0.0	0.0	3.4	100.0
Isosorbide dinitrate		2	0.0	0.0	2.1	.
	Isosorbide dinitrate Tablets 10 mg	1	0.0	0.0	1.5	74.8
	Isordil tablets sublingual 5 mg	0	0.0	0.0	0.5	25.2
Simvastatin		1	0.0	0.0	1.8	.
	Simvastatin Tablets 40 mg	1	0.0	0.0	1.8	100.0
Amiodarone hcl		1	0.0	0.0	1.7	.
	Amiodarone hcl tablets 200 mg	1	0.0	0.0	1.7	100.0
Vitamin D3 (Cholecalciferol)		1	0.0	0.0	1.5	.
	Ostelil capsules 25 mcg	1	0.0	0.0	1.5	100.0
Atenolol		1	0.0	0.0	1.4	.
	Noten tablets 50 mg	1	0.0	0.0	1.4	100.0
Lisinopril		1	0.0	0.0	1.4	.
	Zestril tablets 20 mg	1	0.0	0.0	1.4	100.0
Amlodipine		1	0.0	0.0	1.4	.
	Norvasc tablets 10 mg	1	0.0	0.0	1.4	100.0
Fluvastatin		1	0.0	0.0	1.2	.
	Lescol xl capsules 80 mg	1	0.0	0.0	1.2	100.0
Candesartan cilexetil		1	0.0	0.0	1.2	.
	Atacand tablets 8 mg	1	0.0	0.0	1.2	100.0
Perindopril/Indapamide		1	0.0	0.0	1.0	.
	Coversyl Plus tablets 5.25 mg	1	0.0	0.0	1.0	100.0
Enoxaparin		1	0.0	0.0	0.6	.
	Clexane NOS	1	0.0	0.0	0.6	100.0
Oxygen		1	0.0	0.0	0.6	.
	Oxygen	1	0.0	0.0	0.6	100.0
Frusemide (Furosemide)		0	0.0	0.0	0.6	.
	Lasix tablets 20 mg	0	0.0	0.0	0.6	100.0
Ezetimibe		0	0.0	0.0	0.5	.
	Ezetrol tablets 10 mg	0	0.0	0.0	0.5	100.0
Irbesartan		0	0.0	0.0	0.4	.
	Avapro tablets 150 mg	0	0.0	0.0	0.4	100.0

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 8.4: Prescribed daily dose (generic level)* - New IHD 45+ Apr07-Mar08 wgttd

Generic label	n	Mean PDD	Measure	Lower 95% CI	Upper 95% CI	Median PDD	Minimum	Maximum
Aspirin cardiovascular	9	100.0	mg	100.0	100.0	100.00	100.00	100.00
Metoprolol	9	78.9	mg	40.1	117.7	50.00	25.00	200.00
Rosuvastatin	4	11.1	mg	7.6	14.7	10.00	10.00	20.00
Clopidogrel	4	75.0	mg	75.0	75.0	75.00	75.00	75.00
Perindopril	3	3.5	mg	0.0	7.5	2.50	2.50	5.00
Ramipril	3	3.2	mg	0.0	11.1	2.50	2.50	5.00
Isosorbide mononitrate	3	60.0	mg	.	.	60.00	60.00	60.00
Simvastatin	1	40.0	mg	.	.	40.00	40.00	40.00
Amiodarone hcl	1	200.0	mg	.	.	200.00	200.00	200.00
Atorvastatin	1	80.0	mg	.	.	80.00	80.00	80.00
Isosorbide dinitrate	1	40.0	mg	.	.	40.00	40.00	40.00
Atenolol	1	32.4	mg	.	.	25.00	25.00	50.00
Lisinopril	1	40.0	mg	.	.	40.00	40.00	40.00
Amlodipine	1	10.0	mg	.	.	10.00	10.00	10.00
Fluvastatin	1	80.0	mg	.	.	80.00	80.00	80.00
Candesartan cilexetil	1	8.0	mg	.	.	8.00	8.00	8.00
Perindopril/Indapamide	1	5.3	mg	.	.	5.25	5.25	5.25
GTN (glyceryl trinitrate)	1	5.0	mg	.	.	5.00	5.00	5.00
Frusemide (Furosemide)	0	20.0	mg	.	.	20.00	20.00	20.00
Ezetimibe	0	10.0	mg	.	.	10.00	10.00	10.00
Irbesartan	0	150.0	mg	.	.	150.00	150.00	150.00

* This table includes medications prescribed by GPs.

The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 9.1.1: Top 10 Clinical treatments - IHD 45+ Apr07-Mar08 wgt'd

Clinical treatments	n	% of total Clinical treatments for all IHD 45+ probs		Per 100 IHD 45+ problems		Lower 95% CI	Upper 95% CI
		Lower 95% CI	Upper 95% CI	Lower 95% CI	Upper 95% CI		
Advice/education*	26	20.4	12.2	28.6	2.6	1.5	3.7
Counselling - problem*	23	17.9	9.6	26.3	2.3	1.2	3.4
Counsel/advice - nutrition/weight*	20	15.4	8.1	22.7	1.9	0.9	3.0
Advice/education - medication*	17	13.3	5.9	20.7	1.7	0.7	2.6
Other admin/document*	17	12.9	5.9	19.9	1.6	0.7	2.5
Counsel/advice - exercise*	7	5.1	1.4	8.7	0.6	0.1	1.1
Counsel/advice - smoking*	5	3.5	0.0	7.0	0.4	0.0	0.9
Consultation with primary care provider*	4	2.9	0.0	6.1	0.4	0.0	0.8
Counsel/advice - alcohol*	2	1.7	.	.	0.2	.	.
Counsel/advice - life style*	2	1.6	.	.	0.2	.	.
.
Subtotal	122	94.7
.
Other Clinical treatments	7	5.3
.
Total Clinical treatments	128	100.0	.	.	12.6	9.7	15.5

* Includes multiple ICPC-2 or ICPC-2 PLUS codes
See explanatory notes (Section 3) for URL where groupings are described

Table 9.1.2: Top 10 Procedural treatments - IHD 45+ Apr07-Mar08 wgt'd

Procedural treatments	n	% of total Procedural treatments for all IHD 45+ probs	% of total Procedural treatments for all IHD 45+ probs		Per 100 IHD 45+ problems	Per 100 IHD 45+ problems	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Electrical tracings*	33	57.6	38.6	76.6	3.3	2.0	4.6
INR test	9	15.9	0.0	37.7	0.9	0.0	2.3
Local injection/infiltration*	7	11.7	0.2	23.1	0.7	0.0	1.4
Check-up - PN/AHW*	4	6.8	0.0	15.3	0.4	0.0	0.9
Incision/drainage/flushing/aspiration/removal body fluid*	2	4.0	.	.	0.2	.	.
Physical function test*	1	2.1	.	.	0.1	.	.
Glucose test	1	1.0	.	.	0.1	.	.
Other therapeutic procedures/surgery NEC*	1	0.9	.	.	0.1	.	.

Subtotal	58	100.0

Total Procedural treatments	58	100.0	.	.	5.7	3.6	7.9

* Includes multiple ICPC-2 or ICPC-2 PLUS codes
See explanatory notes (Section 3) for URL where groupings are described

Table 9.2.1: Top 10 Clinical treatments - New IHD 45+ Apr07-Mar08 wgt

Clinical treatments	n	% of total Clinical treatments for new IHD		Per 100 new IHD 45+		Lower 95% CI	Upper 95% CI
		45+ probs	Lower 95% CI	Upper 95% CI	problems		
Counselling - problem*	4	28.2	1.7	54.7	5.1	0.1	10.0
Counsel/advice - nutrition/weight*	3	20.5	1.3	39.6	3.7	0.0	7.6
Advice/education*	3	19.4	.	.	3.5	.	.
Counsel/advice - smoking*	2	10.9	.	.	2.0	.	.
Advice/education - medication*	1	6.8	.	.	1.2	.	.
Other admin/document*	1	6.4	.	.	1.1	.	.
Consultation with primary care provider*	1	5.3	.	.	1.0	.	.
Counsel/advice - exercise*	0	2.5	.	.	0.4	.	.
Subtotal	15	100.0
Total Clinical treatments	15	100.0	.	.	17.9	7.2	28.6

Table 9.2.2: Top 10 Procedural treatments - New IHD 45+ Apr07-Mar08 wgt

Procedural treatments	n	% of total Procedural treatments for new IHD		Per 100 new IHD 45+		Lower 95% CI	Upper 95% CI
		45+ probs	Lower 95% CI	Upper 95% CI	problems		
Electrical tracings*	19	84.5	70.0	98.9	21.8	12.7	30.8
Local injection/infiltration*	2	7.5	.	.	1.9	.	.
Incision/drainage/flushing/aspiration/removal body fluid*	1	5.6	.	.	1.5	.	.
Other therapeutic procedures/surgery NEC*	1	2.4	.	.	0.6	.	.
Subtotal	22	100.0
Total Procedural treatments	22	100.0	.	.	25.8	14.1	37.4

* Includes multiple ICPC-2 or ICPC-2 PLUS codes
See explanatory notes (Section 3) for URL where groupings are described

Table 10.1.1: Top 10 Referrals to medical specialists - IHD 45+ Apr07-Mar08 wgt

Referrals to specialists	n	% of total Referrals to specialists for all IHD 45+ probs	% of total Referrals to specialists for all IHD 45+ probs		Per 100 IHD 45+ problems	% of total Referrals to specialists for all IHD 45+ probs	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Referral;cardiologist	100	92.2	86.5	97.9	9.8	7.6	12.0
Referral;physician	2	2.0	.	.	0.2	.	.
Referral;ophthalmologist	2	1.7	.	.	0.2	.	.
Referral;surgeon	1	1.4	.	.	0.1	.	.
Referral;cardiothoracic surgeo	1	1.3	.	.	0.1	.	.
Referral;specialist	1	0.8	.	.	0.1	.	.
Referral;urologist	1	0.6	.	.	0.1	.	.
Subtotal	108	100.0
Total Referrals to specialists	108	100.0	.	.	10.6	8.4	12.8

Table 10.1.2: Top 10 Referrals to allied health professionals - IHD 45+ Apr07-Mar08 wgt

Referrals to allied health	n	% of total Referrals to allied health for all IHD 45+ probs	% of total Referrals to allied health for all IHD 45+ probs		Per 100 IHD 45+ problems	% of total Referrals to allied health for all IHD 45+ probs	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Referral;podiatrist/chiropodis	3	51.0	.	.	0.2	.	.
Referral;nurse	2	32.0	.	.	0.2	.	.
Referral;occupational therap	1	17.0	.	.	0.1	.	.
Subtotal	5	100.0
Total Referrals to allied heal	5	100.0	.	.	0.5	0.0	1.1

Table 10.2.1: Top 10 Referrals to medical specialists -New IHD 45+ Apr07-Mar08 wgt

Referrals to specialists	n	% of total Referrals to specialists for new IHD 45+ probs	Lower	Upper	Per 100	Lower	Upper
			95% CI	95% CI	new IHD 45+ problems	95% CI	95% CI
Referral;cardiologist	26	91.4	79.0	100.0	30.6	20.4	40.9
Referral;cardiothoracic surgeo	1	5.0	.	.	1.7	.	.
Referral;surgeon	1	3.6	.	.	1.2	.	.
.
Subtotal	29	100.0
.
Total Referrals to specialists	29	100.0	.	.	33.5	23.0	44.1

Table 10.2.2: Top 10 Referrals to allied health professionals -New IHD 45+ Apr07-Mar08 wgt

Referrals to allied health	n	% of total Referrals to allied health for new IHD 45+ probs	Lower	Upper	Per 100	Lower	Upper
			95% CI	95% CI	new IHD 45+ problems	95% CI	95% CI
NIL							

Table 11.1.1: Pathology orders across MBS pathology groups- IHD 45+ Apr07-Mar08 wgt

pathology	n	% of total pathology for IHD 45+ probs	% of total pathology for IHD 45+ probs		Per 100 IHD 45+ probs	Per 100 IHD 45+ probs	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Chemistry	314	81.2	77.3	85.0	30.9	24.3	37.4
Haematology	60	15.6	12.0	19.1	5.9	4.0	7.8
Other NEC	12	3.0	0.8	5.2	1.1	0.3	1.9
Microbiology	1	0.3	.	.	0.1	.	.
Subtotal	387	100.0
Total pathology	387	100.0	.	.	38.0	30.3	45.7

Table 11.1.2: Pathology orders at individual test level- IHD 45+ Apr07-Mar08 wgt

pathology	n	% of total pathology for IHD 45+ probs	Lower 95% CI	Upper 95% CI	Per 100 IHD 45+ probs	Lower 95% CI	Upper 95% CI
Lipids	106	27.4	23.6	31.2	10.4	8.0	12.9
Full blood count	48	12.5	9.4	15.5	4.7	3.2	6.3
EUC	46	11.8	8.9	14.8	4.5	3.0	6.0
Liver function	39	10.1	7.4	12.8	3.8	2.5	5.2
Glucose tolerance	32	8.4	5.8	10.9	3.2	1.9	4.4
Multibiochemical analysis	25	6.6	4.0	9.2	2.5	1.4	3.6
Cardiac enzymes	19	4.9	2.5	7.2	1.8	0.9	2.8
Chemistry; other	14	3.7	1.4	5.9	1.4	0.5	2.2
Thyroid function	9	2.5	0.8	4.1	0.9	0.3	1.6
Coagulation	9	2.3	0.4	4.3	0.9	0.1	1.6
Blood test	8	2.1	0.3	3.9	0.8	0.1	1.5
HbA1c	5	1.3	0.2	2.3	0.5	0.1	0.9
Prostate specific antigen	4	1.1	0.1	2.1	0.4	0.0	0.8
Drug assay	4	0.9	0.0	2.2	0.4	0.0	0.8
Other test NEC	3	0.9	0.0	2.1	0.3	0.0	0.8
Ferritin	3	0.8	.	.	0.3	.	.
Haemoglobin	2	0.5	.	.	0.2	.	.
Test albumin/creatinine, urine	2	0.5	.	.	0.2	.	.
Vitamin D	2	0.5	.	.	0.2	.	.
Calcium/phosphate/magnesium	1	0.3	.	.	0.1	.	.
C reactive protein	1	0.3	.	.	0.1	.	.
Urate/uric acid	1	0.3	.	.	0.1	.	.
Microbiology; other	1	0.3	.	.	0.1	.	.
ESR	1	0.2	.	.	0.1	.	.
Subtotal	387	100.0
Total pathology	387	100.0	.	.	38.0	30.3	45.7

Table 11.2.1: Pathology orders across MBS pathology groups-new IHD 45+ Apr07-Mar08 wgt'd

pathology	n	% of total pathology for new IHD 45+ probs		Per 100 new IHD 45+ probs			
		Lower 95% CI	Upper 95% CI	Lower 95% CI	Upper 95% CI		
Chemistry	41	79.7	69.0	90.3	48.3	25.3	71.2
Haematology	7	14.2	5.5	22.9	8.6	1.5	15.7
Other NEC	3	6.1	0.0	14.5	3.7	0.0	8.3
Subtotal	52	100.0
Total pathology	52	100.0	.	.	60.6	32.8	88.3

Table 11.2.2: Pathology orders at individual test level-new IHD 45+ Apr07-Mar08 wgt'd

pathology	n	% of total pathology for new IHD 45+ probs		Per 100 new IHD 45+ probs			
		Lower 95% CI	Upper 95% CI	Lower 95% CI	Upper 95% CI		
Lipids	9	16.7	4.2	29.3	10.1	1.5	18.8
Chemistry; other	8	15.6	5.3	25.8	9.4	2.5	16.4
Full blood count	6	12.4	5.3	19.5	7.5	1.4	13.6
Multibiochemical analysis	5	10.3	1.7	18.8	6.2	0.8	11.6
Glucose tolerance	4	7.8	1.4	14.2	4.7	0.1	9.4
Cardiac enzymes	4	7.7	0.5	14.9	4.7	0.6	8.7
Liver function	3	6.4	0.7	12.0	3.9	0.0	7.7
Blood test	3	6.1	0.0	14.5	3.7	0.0	8.3
EUC	3	4.9	.	.	3.0	.	.
Ferritin	2	4.4	.	.	2.7	.	.
HbA1c	2	3.0	.	.	1.8	.	.
Haemoglobin	1	1.8	.	.	1.1	.	.
C reactive protein	1	1.6	.	.	0.9	.	.
Thyroid function	1	1.2	.	.	0.8	.	.
Subtotal	52	100.0

Total pathology	52	100.0	.	.	60.6	32.8	88.3
-----------------	----	-------	---	---	------	------	------

Table 12.1.1: Imaging tests ordered by MBS group - IHD 45+ Apr07-Mar08 wgt'd

imaging	n	% of total imaging for IHD 45+		Per 100 IHD 45+		Lower 95% CI	Upper 95% CI
		probs	Lower 95% CI	Upper 95% CI	probs		
Group I3 Diagnostic radiology	10	41.3	14.6	68.1	1.0	0.2	1.8
Group I4 Nuclear medicine imaging	6	26.7	2.0	51.4	0.6	0.0	1.3
Group I1 Ultrasound	6	26.3	4.2	48.4	0.6	0.1	1.2
Group I2 Computerised tomography	1	5.7	.	.	0.1	.	.
Subtotal	24	100.0
Total imaging	24	100.0	.	.	2.4	1.2	3.6

Table 12.1.2: Imaging tests ordered at ICPC-2 PLUS level - IHD 45+ Apr07-Mar08 wgt'd

imaging	n	% of total imaging for IHD 45+		Per 100 IHD 45+		Lower 95% CI	Upper 95% CI
		probs	Lower 95% CI	Upper 95% CI	probs		
X-ray;chest	8	33.6	8.3	58.8	0.8	0.1	1.5
Scan;thallium heart	4	16.1	0.0	38.5	0.4	0.0	0.9
Echocardiography	3	10.5	.	.	0.3	.	.
Test;doppler carotid	2	8.9	.	.	0.2	.	.
Angiogram	2	7.8	.	.	0.2	.	.
Isotope scan	2	6.7	.	.	0.2	.	.
Ultrasound;abdomen	1	5.1	.	.	0.1	.	.
CT scan;cardiac	1	4.0	.	.	0.1	.	.
Nuclear medicine	1	3.9	.	.	0.1	.	.
Ultrasound;inguinal	0	1.8	.	.	0.0	.	.
CT scan	0	1.6	.	.	0.0	.	.
Subtotal	24	100.0
Total imaging	24	100.0	.	.	2.4	1.2	3.6

Table 12.2.1: Imaging tests ordered by MBS group - New IHD 45+ Apr07-Mar08 wgt'd

imaging	n	% of total imaging for new IHD 45+ probs	Lower 95% CI	Upper 95% CI	Per 100 new IHD 45+ probs	Lower 95% CI	Upper 95% CI
Group I3 Diagnostic radiology	4	41.6	0.0	87.6	4.2	0.0	8.9
Group I4 Nuclear medicine imaging	3	32.7	.	.	3.3	.	.
Group I1 Ultrasound	1	14.4	.	.	1.5	.	.
Group I2 Computerised tomography	1	11.3	.	.	1.1	.	.
.
Subtotal	9	100.0
.
Total imaging	9	100.0	.	.	10.0	2.8	17.3

Table 12.2.2: Imaging tests ordered at ICPC-2 PLUS level - New IHD 45+ Apr07-Mar08 wgt'd

imaging	n	% of total imaging for new IHD 45+ probs	Lower 95% CI	Upper 95% CI	Per 100 new IHD 45+ probs	Lower 95% CI	Upper 95% CI
X-ray;chest	4	41.6	0.0	87.6	4.2	0.0	8.9
Scan;thallium heart	3	32.7	.	.	3.3	.	.
Echocardiography	1	14.4	.	.	1.5	.	.
CT scan;cardiac	1	11.3	.	.	1.1	.	.
.
Subtotal	9	100.0
.
Total imaging	9	100.0	.	.	10.0	2.8	17.3